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The development of a novel technique to evaluate binding between 
probiotic bacteria and phospholipids, and the creation of a dairy-based 
food product rich in milk bioactives 
Megan Ann Cleveland 
 Probiotic bacteria are increasingly prevalent in food and nutritional products 
today.  These remarkable microorganisms are capable of imparting exceptional health 
benefits on their host, including prevention of infection by pathogens and stimulation of 
immune system function.  Their most common mode of delivery is through dairy 
products (e.g. yogurt), which are also one of their preferred habitats.  The interactions 
between probiotic bacteria and dairy systems have been studied, but are still not well 
discerned.  There is a need for better understanding of these associations, as well as those 
surrounding the mode of bacterial transfer from the food product to the human 
gastrointestinal tract.  Discoveries into the optimal means of probiotic transport to the 
body may lead to great advancements in both the design of probiotic foods and their 
exploitation in the support of human health. 
 Much of the previous research on probiotic bacteria has explored their possible 
means of adherence in the intestine, as well their strengths in the promotion of human 
health.  Studies relating to their interaction with dairy products are lacking, however, thus 
this work aims to elucidate some of these aspects.  The primary endeavor of this thesis 
was to develop a technique to quantify the binding affinity of probiotic lactic acid 
bacteria for milk phospholipids.  An additional objective was to exploit these bacteria, as 
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well as dairy ingredients rich in bioactive molecules, in the creation of a highly nutritious 
food product. 
 In these experiments, a collection of methods were used in progression in order to 
arrive at a novel protocol to assess binding with excellent reproducibility and simplicity.  
These included various membrane blotting techniques, as well as thin-layer 
chromatography.  Essentially, phospholipids from both animal-derived standards and 
milk extracts were applied to a surface (e.g. PVDF membrane), and bacteria were 
incubated with them to allow binding reactions.  The lactic acid bacteria selected for the 
final assays consisted of four strains of Lactobacillus, including L. reuteri (SD2112 and 
T-1), L. acidophilus, and L. casei (LC-10).  Their adhesion to phospholipids was detected 
by either colorimetric or fluorescent labeling systems.  To illustrate this, the final method 
developed was a procedure in which bacteria fluorescently stained with acridine orange 
were allowed to bind to dots of PVDF membrane coated with phospholipids.  The results 
of this study showed that lactic acid bacteria undeniably exhibit selective binding affinity 
for phospholipids as opposed to other lipids such as triglycerides.  The bacteria 
demonstrated significantly greater binding for a phospholipid extract from milk as 
opposed to individual phospholipid standards from other sources (p<0.05).  Nonetheless, 
adhesion to all phospholipids was substantially greater than that to triglycerides.  These 
findings, as well as the development of this method, should prove valuable in future 
research regarding the associations of probiotics with dairy systems. 
 An additional purpose of this thesis was to design a dairy-based food product 
containing ingredient sources rich in milk bioactives.  A gel-type product was created 
using primarily colostrum, buttermilk powder, and whey protein isolate, as well as 
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selected strains of Lactobacillus.  With the inclusion of immunoglobulin-rich colostrum, 
the product was analyzed alongside fluid milk and colostrum in order to quantify and 
compare these bioactive molecules.  An enzyme-linked immunosorbent assay (ELISA) 
was used to complete this, and the results revealed concentrations that would be expected 
by the literature.  Specifically, immunoglobulin G (IgG) was quantified by interpolation 
from a bovine IgG standard regression curve.  The results showed that the concentration 
of IgG in the gel was nearly twice that of colostrum, and almost eight-fold higher than 
that of milk.  This indicates that use of bioactive-rich substances, such as colostrum, in a 
food product may serve as a means of delivering more concentrated doses of bioactives 
than their respective ingredients. 
 The research completed in this thesis is significant in that it contributes a valuable 
method to the elucidation of bacterial binding interactions with milk components, and 
also demonstrates the successful application of dairy ingredients to an innovative food 
product high in beneficial compounds.  The insight provided by these studies could 
encourage further work in improving the understanding of probiotic delivery and 
advancing the development of bioactive-rich food products. 
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1.0  Introduction 
Milk and dairy products are exceptional sources of an array of biologically active 
compounds that can confer important benefits on human health.  Some of these include 
immunoglobulins, whey proteins and peptides, polar lipids (e.g. phospholipids), and 
lactic acid bacteria.  Probiotics, which include many types of lactic acid bacteria, are 
capable of augmenting the normal community of microflora in the human body and can 
impart considerable health benefits.  Numerous studies have been completed that 
demonstrate some of the remarkable properties of milk bioactives, such as antimicrobial, 
anticarcinogenic, neurological, and immune system enhancing effects.  Due to the 
increasing consumer knowledge of the positive impact of functional foods on health, 
there is a demand for more and better food products to effectively deliver these unique 
compounds. 
 Understanding the interactions between bioactive constituents and their delivery 
matrix may improve the success of the means by which they are transported to the human 
body.  Specifically, discovering the associations among probiotic lactic acid bacteria, 
dairy products, and the intestine is likely to prove valuable in the design of dairy foods 
that provide optimal probiotic benefits.  Thus far, research on probiotics has focused 
primarily on their effects in the host and few studies have concentrated in depth on their 
interaction with dairy products.  To describe these relationships, as well as the 
mechanisms by which lactic acid bacteria may transfer from the dairy product to the 
intestine, the means of probiotic interactions with both mediums must be exposed.  
Existing research has described adhesion mechanisms of probiotics in the intestine by 
means of certain proteins such as mucins and S-layer proteins (Kirjavainen et al. 1998; 
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Deepika and Charalampopoulos 2010).  Some studies have also been conducted that 
reveal the presence of binding between the bacteria and certain components of the milk 
fat globule membrane (Bachiero et al. 2007; Brisson et al. 2010). 
 The primary purpose of this thesis was to develop a method to quantify binding 
between probiotic lactic acid bacteria and milk phospholipids.  A secondary objective of 
these studies was to apply some of the highly bioactive dairy ingredients to the creation 
of a high-value food product.  Expectations for this work relate to these purposes, and 
include the detection of naturally selective binding between probiotic bacteria and 
phospholipids, as well as the successful use of dairy in a bioactive food product.  Insight 
into the associations between probiotics and lipids could be used in science-based 
decisions regarding their selection, as well as that of other ingredients, for inclusion in 
food product formulations.  The hope is that this research will contribute to the current 
relatively small base of knowledge about these complex interactions, and encourage 
further studies that prove beneficial to the advancement of probiotic delivery through 
dairy foods.   
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2.0  Literature Review 
2.1  Milk Bioactives 
2.1.1  Overview of Milk Bioactives 
 Milk is a rich source of biologically active molecules which can have an 
important impact on human health.  Some types of bioactive compounds include certain 
peptides and proteins, oligosaccharides, lactoferrin, lysozyme, minor lipids, and 
immunoglobulins (Park 2009).  One of the rich sources of bioactives is the milk fat 
globule membrane (MFGM), which surrounds fat globules in milk and contributes to 
their emulsification and protection.  The MFGM’s complex structure consists of distinct, 
highly bioactive collections of polar lipids (40%) and minor proteins (60%) (Keenan et 
al. 1988; Fox and McSweeney 1998; Dewettinck et al. 2008).  Milk bioactives such as 
these can have numerous positive impacts on the function and health of the 
gastrointestinal tract and the immune system.  More specific examples of their 
capabilities include improved immune response, bolstered phagocyte activity, enhanced 
growth of bifidobacteria in the intestine, increased natural killer cell activity, provision of 
passive immunity, and reduced attachment of bacteria and viruses in the intestine (Park 
2009).  Some of the primary bioactives of interest in this review include phospholipids, 
caseins and whey proteins, and immunoglobulins. 
2.1.1  Phospholipids 
 Phospholipids are a key building block of cellular membranes, including the milk 
fat globule membrane (MFGM), and are categorized as polar lipids.  They are especially 
concentrated in brain tissue and bone marrow, but also in milk (Rombaut and Dewettinck 
2006).  The major classes of phospholipid include sphingophospholipids (sphingomyelin, 
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SM) and glycerophospholipids (phosphatidylethanolamine (PE), phosphatidylinositol 
(PI), phosphatidylserine (PS), and phosphatidylcholine (PC)).  Ceramides and 
gangliosides are other types of polar lipids and are distinguished by their inclusion of 
hexose sugars.  PC, PE, and SM are the main phospholipids found in bovine milk (Fox 
and McSweeney 2006).  
Phospholipids are unique in that they are amphiphilic, meaning that they possess 
both hydrophilic and hydrophobic properties, which are due to the anionic polar 
phosphate group and fatty acid chains, respectively (Figure 2.1).  The structure of 
glycerophospholipids, such as PC and PE, consists of two fatty acids linked by ester 
bonds to a glycerol backbone.  The subtypes then differ from one another by their 
respective fatty acids and polar head group (Figure 2.1).  In contrast, SM is built upon a 
sphingoid base (typically sphingosine) that is bonded to a fatty acid chain and 
phosphocholine (Figure 2.2).  In regard to fatty acid composition, SM is heavily saturated 
(97%), while among the glycerophospholipids, PC, PS, and PI are the most saturated 




Figure 2.1.  General glycerophospholipid structure and subtypes (Nelson and Cox 2000). 
 
 
Figure 2.2.  General sphingolipid structure.  “X” represents the side group that defines the 
specific type of sphingolipid (Nelson and Cox 2000). 
 
Phospholipids represent 0.5-1.0% of total milk fat.  The majority (60-65%) are 
found in the intact milk fat globule membrane (MFGM), while the rest are found in 
protein and membrane fragments in solution.  Phospholipids account for 15-30% of the 
MFGM (Fox and McSweeney 2006).  The distribution of some of the major 
phospholipids in the MFGM is as follows: PC (35%), PE (30%), SM (25%), PI (5%), and 
PS (3%) (Deeth 1997; Danthine et al. 2000).  During milk processing, phospholipids are 
distributed in different ratios to each milk fraction.  As a percentage of the total lipid 
content, the highest ratios of phospholipid are found in buttermilk and skim milk, due to 
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the amount of MFGM material in these products.  However, butter, cream, and buttermilk 
contain the greatest percentage of phospholipids in a weight/volume ratio (Fox and 
McSweeney 1998). 
The health benefits of polar lipids and their metabolites are numerous.  They 
include positive effects on the function of the immune system, heart, and brain, as well as 
anti-cancer mechanisms.  Phospholipids have antioxidative, antimicrobial, and antiviral 
properties, in addition to instrumental roles as secondary messengers for cell signaling, 
regulation, and growth (Pettus et al. 2004; Fox and McSweeney 2006).  Phospholipids 
can protect against stomach ulcers and adhesion of pathogenic gram-positive bacteria, 
such as Listeria monocytogenes, particularly by buttermilk-derived phospholipids in the 
latter case (Fox and McSweeney 2006).  Sphingolipids are also noteworthy in the realms 
of antibacterial, anticancer, and hypocholesterolemic effects.  SM holds the potential for 
significant anti-tumor effects (Rombaut and Dewettinck 2006).  This occurs primarily 
through the ability of SM metabolites (ceramide and sphingosine) to induce cellular 
growth prohibition, differentiation, and apoptosis.  Sphingolipids protect against infection 
by bacterial toxins and viruses by competitive binding to these invaders before they can 
bind to epithelial cells (Dewettinck et al. 2008). 
In addition to the incredible roles of phospholipids in health promotion, these 
lipids possess a unique set of nutritional and technological functions.  Nutritionally, these 
include brain and liver cell nourishment and reduction of blood lipid levels.  
Phosphatidylcholine (PC) also provides choline to the bloodstream, which is essential in 
the synthesis of acetylcholine, a crucial neurotransmitter for muscle function, memory, 
and other cognitive processes (Schmitt 2008).  Some of the technological functions of 
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phospholipids are demonstrated in lecithins, compounds naturally found in plant and 
animal foods.  In lecithins and on their own, phospholipids are largely responsible for 
emulsification, stabilization, and foaming (Schmitt 2008).  In food products, milk fat 
globule membrane (MFGM) isolates, which include phospholipids, may serve as good 
emulsifiers or fat replacers.  For example, an emulsion mimicking cream can be formed 
by combining 2% MFGM material with 25% milk fat (Kanno 1989).  Phospholipids can 
impart either prooxidant or antioxidant effects to foods, depending on the type, pH, and 
water concentration.  For instance, due to the inclusion of monounsaturated and 
polyunsaturated fatty acids, phospholipids can bind to metal ions, resulting in lipid 
oxidation, especially with the presence of heat (Fox and McSweeney 2006).  However, 
the large assortment of phospholipids benefits outweighs the aforementioned negative 
effects by far.  Because of the combined technological and nutritional benefits of 
phospholipids, they present excellent potential for use in functional foods (Schmitt 2008). 
2.1.2  Caseins and whey proteins 
 Caseins and whey proteins are rich sources of bioactive peptides.  Bovine milk 
consists of about 3.5% protein, of which approximately 80% is casein and 20% is whey 
proteins.  Each of these proteins is classified into numerous subtypes, including α-, β-, 
and κ-caseins, and many types of whey proteins.  Some of the whey proteins include α-
lactalbumins and β-lactoglobulins (18% and 48%, respectively), immunoglobulins (12%), 
and serum albumin (6%) (Swaisgood 1993; Tremblay et al. 2003).  These bioactives are 
found in both milk and colostrum, but they are much more concentrated in the latter 
(Korhonen 2009).  Lactalbumins and lactoglobulins are the two major fractions of whey, 
and can be distinguished by their chemical behavior; the former are soluble in 50% 
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saturated (NH4)2SO4 or saturated MgSO4, while the latter come out of solution as salts 
under these conditions.  The immunoglobulins are concentrated mainly in the 
lactoglobulin fraction, while serum albumins collect with the lactalbumins (Neyestani et 
al. 2003; Saito 2009). 
During cheesemaking, milk proteins are separated into their respective types, with 
casein comprising the cheese curd, and whey proteins concentrated in the resulting liquid.  
This liquid, aptly named whey, can then be made into a variety of powder forms to 
concentrate and preserve the proteins, including whey protein concentrate (WPC) and 
whey protein isolate (WPI).  If the physicochemical properties of whey proteins are well 
understood, these proteins can be applied in food product innovations due to their 
functionality in gelation, foaming, emulsification, stabilization, and water-holding (Ko 
and Kwak 2009).  For instance, native α-lactalbumin is a good emulsifier, and native β-
lactoglobulin results in exceptional gelation and foaming (Korhonen et al. 1998). 
Whey proteins are a high-quality protein due to their overall amino acid 
composition, and high level (26%) of branched-chain amino acids (BCAAs).  These 
amino acids, including leucine, isoleucine, and valine, are potent stimulators of protein 
synthesis and energy production in skeletal muscle tissue, and are only metabolized in the 
muscle.  Leucine has also been found capable of increasing insulin secretion by adjusting 
the concentration of this hormone in the blood, and is also key in regulating the 
metabolism of amino acids and proteins (Ko and Kwak 2009).  Whey proteins have also 
been shown beneficial in exercise performance and muscle recovery, satiety and weight 
control, stress relief, cognitive function, cancer prevention, and wound healing 
(Korhonen 2009). 
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As part of the whole protein molecule the amino acid sequences comprising 
casein and whey peptides are inactive, but once released they possess significant value.  
Bioactive peptides are typically released from their precursor proteins by digestive 
enzyme hydrolysis, proteolysis by fermentative starter cultures or other microbes, or by 
some combination thereof.  The most common of the digestive enzymes involved are 
pepsin, trypsin, and chymotrypsin.  Starter cultures used in yogurt and cheese have been 
shown to liberate a variety of potent bioactive peptides (Korhonen 2009).  Their functions 
consist of antimicrobial, antihypertensive (ACE-inhibitory), antithrombotic, 
antioxidative, anticytotoxic, probiotic, binding vitamins and minerals for improved 
absorption, hypocholesterolemic activity, and immune supportive effects (Ko and Kwak 
2009; Park 2009).  WPC has exhibited anticarcinogenic effects by providing amino acids 
that stimulate the production of glutathione, a natural cellular peptide that enhances 
immune activity (Ko and Kwak 2009). 
2.1.3  Immunoglobulins and colostrum 
 Immunoglobulins (Ig) are a highly beneficial fraction of whey proteins.  They are 
most highly concentrated in colostrum (70-80% of total protein compared to 1-2% in 
milk) and carry out the functions of antibodies by providing passive immunity against 
pathogens (Korhonen et al. 2000).  Each class of immunoglobulin shares a similar 
fundamental Y-shaped structure consisting of four chains, two heavy and two light, 
which are associated by disulfide bonds.  These subtypes and their respective 
concentrations in milk are shown in Table 2.1 (Larson 1992; Hurley 2003).  For 
comparison, the total concentration of immunoglobulins in colostrum ranges from 0.7 to 
10 mg/ml within a few days of parturition, although initially it is much higher (Saito 
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2009).  The subtype IgG1 is the most abundant in bovine milk as well as colostrum, 
where it initially represents over 90% of immunoglobulins (Hurley 2003). 
Table 2.1:  Immunoglobulin subtypes and concentrations in milk (Hurley 2003). 
Immunoglobulin class Concentration in milk (mg/ml) 






The functions of immunoglobulins include prevention of pathogen adhesion to 
epithelial cells and the prevention of pathogen survival, agglutination of bacteria, and 
neutralization of toxins and viruses (Korhonen 2009).  Immunoglobulin G (IgG) holds 
the highest concentration of the subtypes in milk, is 150 kDa, and is well-studied.  Bovine 
milk IgG activity has been shown to have comparable effects with human milk IgG in 
promoting immune function (Ko and Kwak 2009).  Research about the efficacy of 
colostral immunoglobulins in disease prevention has shown promising results against 
infections in humans and animals, including those caused by rotavirus, Escherichia coli, 
Clostridium difficile, Candida albicans, and Helicobacter pylori (Korhonen 2009).  One 
of the most important activities of milk IgG is the inhibition of enteropathogenic 
microbes from adhering to epithelial cells in the intestine (Ko and Kwak 2009).  
Retention of IgG bioactivity is of concern during digestion.  Due to the acid pH of 
stomach fluids, immunoglobulin activity is reduced, and once the intestine is reached 
they are enzymatically dissociated into their main constituents.  Fortunately, much of 
their bioactivity is retained in the upper digestive tract, and some inhibitory activity is 
still present in the intestine (Mehra et al. 2006).  Encapsulation techniques can also 
improve retention of immunoglobulin bioactivity and survival (Kelly et al. 1997).  
  11
Clinical trials have not shown negative effects from colostrum supplementation, though 
their regulatory status has not been established in many countries (Mehra et al. 2006). 
As previously noted, bovine colostrum is an excellent source of highly beneficial 
immunoglobulins, especially IgG.  Colostrum is a rich, complex source of many other 
bioactive proteins, as well as lactoferrin and lysozyme, and is produced in mammalian 
mothers just after birth.  This remarkable product has numerous beneficial effects, 
including contributions to the immune system, growth factors, and tissue repair factors.  
It is also implicated in anti-viral (polio, influenza A, herpes simplex) and anti-bacterial 
effects (E. coli, salmonella, streptococcus), as well as wound healing and musculoskeletal 
repair (Uruakpa et al. 2002).   
A number of commercial products exist that exploit the colostrum bioactives, 
particularly the immunoglobulins.  Immunoglobulins are among the most heat-stable 
whey proteins, though this varies with the subtype (IgG being the  most resistant) 
(Dominguez et al. 2001).  Retention of their bioactivity post-processing is of concern, 
however, due to their potential denaturation and loss of associated beneficial functions.  
This seems to be dependent on the processing method.  For instance, experiments on 
commercially-processed milk have shown that immunoglobulin concentrations and 
antigen-binding activities (assessed by ELISA and RID) are preserved with the use of 
batch pasteurization parameters (63ºC for 30 min), but significantly reduced (25-40%) or 
completely lost with treatment by HTST (72ºC for 15 sec) and UHT (138ºC for 4 sec) 
pasteurization processes, respectively (Li-Chan et al. 1995).  Other research suggests that 
immunoglobulin denaturation can be relatively low (1-14%) in response to lab-scale 
HTST treatment (determined by RID) (Mainer et al. 1997).  pH also directly impacts the 
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survival and activity of immunoglobulins, and significant denaturation (31%) has been 
reported when they are solubilized in phosphate buffer and heated at acid pH values (e.g. 
pH 4.5).  However, this effect may be less severe when in the presence of milk or 
colostrum, likely due to inherent protection by milk proteins and salts (Dominguez et al. 
2001).  Chen et al. (2000) found that milk IgG could be significantly stabilized during 
heat processing when in the presence of 20% glycerol, 20% maltose, or 0.2% glutamic 
acid.  The reasons for this protective effect are not certain, but may be related to 
increased hydrophobic interactions in the IgG (Chen et al. 2000).  Microencapsulation 
methods may also improve IgG stability.  Chen et al. (1999) found that multiple 
emulsions, such as water-in-oil-in-water (W/O/W), improved milk IgG stability by 21-
56% against acid (pH 2.0), 33-62% against alkali (pH 12.0), and 35-82% against various 
proteases.  A disadvantage of this process, however, was loss of 41-50% of the IgG used 
to prepare the multiple emulsion. 
2.1.4  Other milk bioactives 
 The activity of milk bioactives is quite impressive.  Other noteworthy compounds 
include lactoferrin, lactoperoxidase, and glycomacropeptide.  Lactoferrin is an iron-
binding glycoprotein found in milk and colostrum, and is of major importance in 
conferring anticancer, anti-inflammatory, and extensive antimicrobial effects.  It is 
suspected to be instrumental in innate immune function against pathogens, stimulation of 
antibody response, prevention of microbial adhesion to epithelial cells, and reduction of 
destructive attack by molecules such as free radicals (Korhonen 2009). 
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 Lactoperoxidase is another glycoprotein, and the chief enzyme in milk.  It can 
generate oxidation products of thiocyanate ions that kill or prevent growth of both 
pathogenic and spoilage bacteria in milk. 
 Glycomacropeptide is a glycopeptide enzymatically derived from κ-casein, and is 
a major peptide found in the whey fraction from cheesemaking. Ample research has 
shown its value in improving immune responses, inactivating microbial toxins, improving 
blood pressure, and promoting the growth of bifidobacteria (Korhonen 2009). 
2.1.5  Bioactive delivery systems 
Nutrition has a significant impact on human health.  It can either improve health 
by reducing disease prevalence or by contributing to quality of life, or it can diminish 
health in the same areas.  Due to the wealth of nutrition and health research, as well as the 
current prevalence of lifestyle-related diseases, many new food products have been 
created to target human wellness.  The main approach to this is the development of 
functional foods, which have gained considerable consumer interest over the last decade 
or so.  These foods are defined as ones that can attribute specific health benefits, such as 
reduction of disease risk, above the capabilities of basic nutrients (Korhonen 2002; Park 
2009).  The trend toward using food as medicine has taken root, and products are now 
designed with multiple targets, including immune defense, digestive health, bone health, 
prevention of heart disease, weight management and loss, and physical performance.  
Commercial manufacture of functional foods requires attention to processing parameters 
to ensure retention of bioactivity, thus new methods have been developed for these 
applications.  This includes non-thermal processes, supercritical fluid extraction, and 
membrane separation techniques (Korhonen 2002). 
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Milk bioactives are important and growing inclusions of the numerous functional 
foods in the consumer marketplace.  Dairy ingredients hold a significant place in this 
arena, especially due to the fact that in addition to being valuable carriers of bioactive 
compounds, dairy products are also good sources of major nutritional proteins.  
Commercial products already exist that are targeted at improving immune function and 
hypertension, as well as assisting in weight control and prevention of gastrointestinal 
infections (Korhonen 2009).  In 2008, the Mintel Group reported that functional dairy 
food product sales increased by over 33% between 2005 and 2007, to a value of $2 
billion, or 75% of overall sales for functional foods.  As of 2008, these sale volumes were 
expected to continue to increase substantially (Park 2009). 
The trend toward high nutrient density foods can be seen by the use of dairy in 
products such as energy bars, yogurt drinks, and nutritional powders.  Certain dairy 
ingredients prevail in providing concentrated and functional sources of bioactives for 
application in food products.  Some of the best ones include buttermilk powder, 
colostrum, and whey protein concentrate (WPC) and isolate (WPI).  Most of these 
represent high-nutrient value products that were previously treated as waste by-products 
from cheese and butter manufacturing.  Through innovation, however, waste has become 
highly profitable.  For instance, cheese whey is commonly made into WPC and WPI and 
exploited in countless food products, including nutrition bars and other sports nutrition-
related and processed foods.  Lesser known perhaps, but with high functionality, is 
buttermilk, the side product of butter manufacture.  When spray-dried into powder, 
buttermilk contains five times the amount of phospholipids as raw milk (on dry basis) 
(Rombaut et al. 2005), and provides exceptional emulsification properties, and protein 
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fortification.  Its addition to bakery mixes and baked goods is well-established, but it has 
great potential to enhance other food products as well (Morin et al. 2007). 
Colostrum is an excellent source of a variety of bioactive proteins, 
immunoglobulins, and other constituents (Uruakpa et al. 2002).  It can be pasteurized and 
either spray-dried or freeze-dried under conditions that retain bioactivity and made into a 
variety of dry powders.  Numerous colostrum-rich nutritional and pharmaceutical 
products have been commercialized throughout the world, many of which are aimed at 
prevention or treatment of intestinal infections, and others for boosting the immune 
system or physical performance.  Some examples of these products include 
GastrogardR™, an Australian pharmaceutical colostrum concentrate for prevention of 
rotavirus-induced diarrhea in children, and ImmuNOVA™, a Finnish drinkable 
colostrum product used in hospitals and by individuals as a nutrition supplement for 
intestinal problems or immune support.  Some research suggests that powerful synergistic 
health effects could result from combinations of bovine immunoglobulins, probiotic 
lactic acid bacteria, lactoferrin, and growth factors (Mehra et al. 2006). 
2.2  Probiotics 
2.2.1  Definition, background, & characteristics 
Probiotics are living microorganisms that can greatly benefit human health when 
consumed in adequate amounts (FAO/WHO 2002).  As far back as ancient times, milk 
products fermented by lactic acid bacteria were prescribed for ailments of the 
gastrointestinal tract and liver.  In the early 1900s, microbiologist and Nobel Prize winner 
Elie Metchnikoff began to elucidate the mechanisms by which these bacteria confer 
health benefits, and promoted their ability to increase human longevity (Jelen and Lutz 
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1998; Jin Baek and Lee 2009).  Fermentation by lactic acid bacteria was believed to 
result in improved gastrointestinal function and nutrient absorption, as well as stimulation 
of the immune system and intestinal flora balance (Jin Baek and Lee 2009).  More 
modern identification of lactic acid bacteria has resulted in the widespread production of 
foods such as yogurt, acidophilus milk, and kefir (Jelen and Lutz 1998). 
LAB are gram-positive, coccus- or rod-shaped bacteria that ferment carbohydrates 
into lactic or acetic acid and carbon dioxide.  They are typically facultative anaerobes, 
meaning that they can produce ATP energy in the presence of oxygen, but given 
anaerobic conditions they switch to fermentation.  Their preferred growth temperature 
depends on the specific species and subtype, but the range is generally 35-38ºC, with 
37ºC optimal for many.  The ideal pH values for growth are slightly acidic, for example, 
5.5-6.0 for Lactobacillus acidophilus.  LAB are represented by multiple bacterial genera, 
including Lactobacillus, Lactococcus, Streptococcus, and Bifidobacterium. Some 
common probiotic species of lactobacillus are L. acidophilus, L. reuteri, L. helveticus, 
and L. rhamnosus.  Bifidobacteria have similar characteristics to lactobacilli, except that 
they are irregularly shaped rods and are their growth requirements are more strict.  They 
are classified as obligate anaerobes because they die in the presence of oxygen, which 
also complicates their viability when added to food and nutritional products (Jin Baek 
and Lee 2009).  Their pH growth range is from 4.5-8.5 (Anal and Singh 2007).  Typical 
probiotic species are B. bifidum, B. infantis, and B. breve.  Both genera of bacteria are 
resistant to bile and are common members of human intestinal microflora (Jin Baek and 
Lee 2009). 
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2.2.2  Probiotics in the human body 
Lactic acid bacteria (LAB) and bifidobacteria are among the most common types 
of probiotics, and are found frequently in fermented dairy products, human mucosa, and 
the natural environment (Jin Baek and Lee 2009).  The human gastrointestinal (GI) tract 
is colonized by a complex community of microflora, including probiotics, and contains 
hundreds of bacterial species in staggering quantities of 1012/g in the colon, or 60% of 
fecal mass (Savage 1977; Simon and Gorbach 1984).  The mucosa of the gastrointestinal 
tract provides an impressive 150-200 m2 to which bacteria can colonize, mainly due to 
the numerous folds, or villi, of the intestine.  This is an incredibly large area compared to 
the 2 m2 of human skin surface (Waldeck 1990).  Moreover, the GI tract is the largest 
immune organ in the body, and the site of production for 80% of the body’s antibodies 
(Saavedra 2007).  Because this is a major site of immune activity, it is understandable 
that the colonization of immune-supportive probiotic bacteria would have significant 
impact on this vital bodily system.  However, a number of factors can negatively impact 
the variety and activity of microflora, including stress, diet, age, disease, and 
medications, such as antibiotics (Jin Baek and Lee 2009).  Thus, consuming viable 
probiotics in sufficient quantities (106-107cfu/g) offers great potential in maintaining and 
restoring the diversity of gut microflora and their extensive benefits (FAO/WHO 2001). 
Probiotic growth and activity can be stimulated in the body by prebiotic 
substances, such as various oligosaccharides, inulin, and β–glucan.  Prebiotics are 
indigestible in the stomach and small intestine, and are specifically utilized by certain 
bacteria in the colon.  A growing number of prebiotics are produced commercially, and 
are derived from plant materials, such as chicory root, beans, and oats (Bomba et al. 
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2002; Su et al. 2007).  Inulin-type fructans are well-suited to fermentation by 
bifidobacteria, and can increase microbiota by as numbers as high as 0.5-1.0 log10 
(Kolida and Gibson 2007).  Prebiotics can resolve challenges with probiotic colonization 
and survival, as well as impart health benefits.  These include improved glucose 
tolerance, regulation of GI transit times, reduction in lipid absorption, and promotion of 
beneficial short-chain fatty acids (SCFA) by resident microbes (Roberfroid 1996).  Due 
to the prevalence of antibiotic-misuse and bacterial resistance, as well as the demand for 
probiotic functional foods, research in the areas of probiotics, prebiotics, and 
combinations thereof has become very important (Jin Baek and Lee 2009). 
The health benefits of probiotic bacteria are certainly outstanding.  They do seem 
to be strain-specific rather than genus- or species-specific, and also enhanced by 
combinations of probiotics (Shah 2007).  Nonetheless, health impacts include 
enhancement of immune system function and intestinal microflora balance, aid in serum 
cholesterol reduction and lactose metabolism, reduction of adhesion and colonization by 
pathogenic bacteria, and improvement of nutrient bioavailability.  Other functions 
involve anticarcinogenic effects, antimicrobial activity, and improvement of intestinal 
inflammatory diseases.  Certain species of bifidobacteria may also prevent the 
development of allergies (Jin Baek and Lee 2009). 
During infancy, the predominant gut microflora are significantly impacted by 
whether breast milk or formula is consumed.  Breast-fed babies’ feces is mainly 
composed of beneficial lactobacilli, bifidobacteria, and staphylococci, while formula-
feeding results in primarily coliforms, enterococci, and bacteriodes (Walker and Duffy 
1998).  Studies have shown that the impact of probiotics on infant immune system 
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development has lifelong benefits, thus the choice of breast-feeding or probiotic formulas 
is critical (Ouwehand et al. 2002).   
Probiotics play a major role in the prevention of diarrheal-related illnesses, as 
well as attributing relief to constipation and inflammatory bowel disease.  Diarrheal 
illness is serious, especially in developing countries, where millions of children die each 
year due to diarrhea caused primarily by the imbalance of beneficial microflora with 
rotavirus and Clostridium difficile.  As previously mentioned, antibiotics also negatively 
impact microflora, resulting in diarrhea in up to 25% of patients.  In children, treatment 
with lactic acid bacterial probiotics such as Lactobacillus rhamnosus GG has been 
effective (Jin Baek and Lee 2009). 
One of the means by which probiotic bacteria protect against invading 
enteropathogens is by inhibiting their growth.  Some of their normal metabolic processes 
produce substances toxic to pathogens, including organic acids (e.g. acetic acid) and 
bacteriocins (Tamura 1983).  The probiotic Lactobacillus reuteri produces an 
antimicrobial during glycerol metabolism called β–hydroxypropionaldehyde (Axelsson et 
al. 1989).  This compound, also known as reuterin, is active against a range of bacteria, 
including strains causing foodborne illness such as Listeria monocytogenes and E. coli 
O157:H7 (Chung et al. 1989; El-Ziney and Debevere 1998).  Probiotic deconjugation of 
bile salts also assists in inhibiting pathogen growth, as well as in the reduction of serum 
cholesterol by preventing its absorption (Jin Baek and Lee 2009).   
Anticarcinogenic probiotic effects have also been suggested.  Clinical trials have 
been inconclusive, however, probiotics may inhibit abnormal cell proliferation by 
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reducing inflammation, improving immune activity, and binding dietary carcinogens 
(Geier et al. 2006). 
Lactose intolerance is another important condition on which probiotics may exert 
a positive impact.  This disorder is attributed to reduction of β-galactosidase (lactase) 
enzymes and/or by loss of small intestinal mucosa, both of which result in severe 
diarrhea, abdominal pain, flatulence, and bloating.  β-galactosidase, which is produced by 
lactic acid bacteria, provides relief from lactose intolerance by catabolizing lactose into 
glucose and galactose (Jin Baek and Lee 2009). 
Colonization of probiotic bacteria to epithelial cells in the intestine has been 
demonstrated to prevent the adherence of certain pathogens (Mukai et al. 2004).  In one 
encouraging study, L. reuteri was successfully used to reduce the duration of rotavirus-
induced diarrhea (Shornikova et al. 1997).  Infants hospitalized for this condition were 
treated with a placebo or one of two quantities of L. reuteri.  After 2 days of treatment, 
the diarrhea continued in just 48% of the subjects treated with large dose of L. reuteri 
(p=0.04; n=21), compared to 80% persistence in the placebo group (n=25).  This study 
exemplifies the potentially powerful benefits of probiotic bacteria in the treatment and 
prevention of disease. 
2.2.3  Adhesion mechanisms of probiotics 
It is well known that bacteria take up residence in multiple regions of the human 
body, especially the digestive tract.  This includes both pathogenic and nonpathogenic 
species, such as Escherichia coli and Lactobacillus reuteri, respectively.  One of the most 
important factors in pathogenic infection is the attachment of the offending 
microorganisms.  Once these pathogens adhere to the intestinal epithelial cells, the 
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processes of colonization, cellular damage, and disrupted cellular mechanisms can begin 
(Coconnier et al. 1993).  These harmful effects can be prevented, however, by lactic acid 
bacteria.  The mechanisms by which probiotic bacteria protect against pathogenic 
infections are not fully understood, but may include reduction in pH, production of 
antimicrobial compounds such as organic acids and bacteriocins, stimulation of the 
immune system, and competition for binding sites and nutrients (Collins and Gibson 
1999).  In order for probiotics to exert beneficial effects, however, they must have 
suitable environmental conditions in the human body as well as the initial means of 
delivery and growth therein.  By examining the means of probiotic binding as well as the 
components to which they bind, fundamental understanding can be gained for the optimal 
parameters needed for delivery of these valuable microorganisms. 
Specific characteristics of the metabolism and physiology of lactobacilli 
determine their adaptation to the host intestinal environment and thus their contribution 
of probiotic benefits (Lebeer et al. 2008).  Surface interactions between lactobacilli and 
intestinal cells occur initially via hydrophobic interactions from afar, and then by specific 
associations involving complementary binding sites once in close proximity (Deepika and 
Charalampopoulos 2010).  The cell wall structure plays a key role in many of the 
proposed mechanisms for lactic acid bacterial binding, and includes binding receptor 
components such as proteins, carbohydrate chains, and enzymes that influence the 
interaction of the bacteria with its environment.  Some of the possible methods of these 
interactions include hydrophobic or electrostatic interactions, passive forces, lipoteichoic 
acids in the cell wall, and other structural means such as lectin-coated appendages (Servin 
and Coconnier 2003).  Another very important contributing structural attribute is the 
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presence of cell surface proteins such as sortase-dependent proteins (SDPs) and S-layer 
proteins (Lebeer et al. 2008). 
S-layer proteins consist of an outer shell of protein subunits arranged in a 
paracrystalline structure that covers much of the cell surface.  The protein constituents of 
the S-layer are identical monomolecules that are generally small (40-200 kDa), have a 
strong tertiary structure, and are typically not glycosylated in lactobacilli (Lebeer et al. 
2008; Deepika and Charalampopoulos 2010).  S-layer proteins are likely a key 
mechanism of binding between bacteria and the intestinal mucosal layer (Deepika and 
Charalampopoulos 2010).  They are present in both gram-positive and gram-negative 
bacteria, thus their contributions to structure and virulence are presumably essential to 
many bacteria.  In fact, pathogen survival may be enhanced by a possible role of the S-
layer in subjugating threats of phagocytosis and bactericidal attacks (Sleytr and 
Beveridge 1999).  In some strains of lactobacilli, research has shown that removal of the 
S-layer greatly hinders bacterial adherence to other substances, which illustrates the 
importance of the S-layer in this area (Sillanpaa et al. 2000; Roos and Jonsson 2002; 
Frece et al. 2005).  Cell surface hydrophobicity and charge are likely to be highly 
influential in determining bacterial adhesion to surfaces, and may be imparted by S-layer 
proteins.  For example, in experiments with L. acidophilus and L. crispatus (both with 
natural S-layers), as well as a recombinant strain of L. casei (previously without an S-
layer), the presence of S-layer proteins was found to significantly increase adhesion to 
hydrophobic, negatively charged hexadecane.  This demonstrates the influential nature of 
cell surface hydrophobicity in Lactobacillus adhesion (van der Mei et al. 2003). 
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Another significant element in the interaction of bacteria with the human 
intestinal tract is the presence of the glycoproteins called mucins.  These are glycosylated 
cell surface proteins that are a major component of the intestinal mucosal layer protecting 
epithelial cells, and also provide an important binding medium for bacteria.  Multiple 
strains of Lactobacillus and Bifidobacterium have been found to attach via interactions 
between carbohydrate moieties and the mucosal surface of the intestine, although the 
overall adhesion mechanisms are still not definite.  Successful colonization of probiotic 
bacteria via binding to the mucosal layer is important because with increased residence 
time in an attached state, the bacteria are allowed more opportunity to infer positive 
health effects on the host (Kirjavainen et al. 1998).  The ability of the bacteria to adhere 
to the intestine may be correlated to its effectiveness in the host.  For example, in a study 
where people were treated with probiotics, their serum antibody titres were directly 
related to the adherence ability of the bacterial strain used for treatment (O'Halloran et al. 
1997). 
Lipids represent a significant component of the mucosal layer, some subtypes of 
which include glycolipids such as glycosphingolipids, neutral lipids, and phospholipids, 
the latter of which include mainly phosphatidylcholine, phosphatidylethanolamine, and 
sphingomyelin (Blomberg et al. 1995).  Glycosphingolipids also function as specific 
binding sites for bacteria, viruses, and certain cellular receptors and enzymes, in addition 
to also having a place in bacterial cell membranes (Huwiler et al. 2000).  These details 
illustrate the important role of lipid subtypes in the achievement of probiotic binding to 
surfaces. 
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Several components of the milk fat globule membrane (MFGM) exhibit an 
affinity for bacterial cell surfaces, including mucins, phospholipids, proteins, 
glycophospholipids, and gangliosides (Deepika and Charalampopoulos 2010).  While the 
means of adhesion of bacterial proteins and other cellular components to the intestinal 
mucosa have been fairly well examined, binding to lipids has been minimally studied.  
Both sources are embedded with a variety of membrane proteins, glycoproteins, 
carbohydrates, enzymes, and phospholipids.  It is important to note that much research 
thus far has been on isolated MFGM, which likely limits the findings that could come 
from studies involving the intact, native membrane (Evers 2004).  Nonetheless, because 
of the similarity in composition between the MFGM and intestinal epithelial cells, it is 
worth exploring the binding mechanisms of probiotic bacteria to the MFGM.  Research in 
this area may provide insight as to why dairy foods serve as natural carriers of these 
bacteria, as well as why they may deserve greater merit for this position over other foods 
(Bachiero et al. 2007). 
Phospholipids and sphingolipids, previously identified in this review as part of the 
intestinal mucosal layer, are a key component of the MFGM.  Lipid-binding thus 
represents a noteworthy area of interest due to the practical application to probiotic 
bacteria incorporated into food matrices, such as milk and dairy products.  Some studies 
have been completed concerning certain influential binding characteristics of bacteria and 
lipids.  One such of these showed that greater bacterial binding to MFGM components is 
associated with the cell surface hydrophobicity (Brisson et al. 2010), although this is not 
always the case (Deepika and Charalampopoulos 2010).  In another study measuring the 
binding affinity of lactic acid bacteria to various dairy lipids, two types of binding were 
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found.  Lactic acid bacteria exhibited definite binding to triglycerides (non-polar) and 
strain-specific, but even more significant binding to phospholipids (polar).  The results of 
this study also display some of the influences of food processing on binding affinity, 
including increased binding in milk powders that have undergone supercritical fluid 
extraction (Bachiero et al. 2007).  Other processing research has revealed that cooling 
milk results in a 20% reduction in phospholipids and heating it results in whey protein 
adsorption, aggregation of minor MFGM proteins, and enzyme denaturation (Ye et al. 
2002).  The results of the aforementioned studies, combined with future work in the 
elucidation of specific binding to phospholipids and other MFGM components, serve as 
practical contributors to the design of probiotic dairy foods with optimal health benefits. 
As previously mentioned, it is important to note that experiments studying 
bacterial adhesion are subject to external factors that affect the physiological state of the 
bacteria.  Many of the aforementioned surface properties of lactobacilli are influenced by 
the fermentation media, time, and conditions, as well as harvesting procedures, storage 
conditions, and the mode of delivery to the targeted location (Deepika and 
Charalampopoulos 2010).  For instance, in the area of food structures, the interaction of 
probiotic bacteria with the food constituents can have an important impact on their 
viability and delivery to the body.  Studies with whey protein products have shown that 
probiotic Lactobacillus rhamnosus GG exhibits improved survival when bound in a 
matrix of whey proteins, even in the hydrolyzed and denatured state.  This environment 
proves protective against storage stresses such as heat and acid.  Yogurt matrices also 
provide effective defense against bacterial losses during storage, likely due to the gelled 
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network (Doherty et al. 2010).  This study provides further reinforcement of the idea that 
dairy is an excellent natural mode of probiotic transport (Tannock 1999). 
2.2.4  Probiotic adhesion and disease prevention 
Numerous studies have demonstrated the effectiveness of probiotic bacteria in 
disease prevention.  For instance, certain lactic acid bacteria have been shown helpful in 
eliminating Staphylococcus aureus, an opportunistic pathogen responsible for a range of 
minor to severe infections of the skin, intestines, and blood.  In one study, S. aureus was 
displaced from human intestinal tissue samples by 39-44% when in the presence of 
Lactobacillus rhamnosus GG, Lactococcus lactis subsp. lactis, and Propionibacterium 
freudenreichii subsp. shermanii JS.  Lactobacillus reuteri ING1 reduced this pathogen’s 
viability by 27% after 2 hours incubation, likely due to its production of antimicrobial 
reuterin (Vesterlund et al. 2006).  These results show that treatment of infections with 
particular probiotic bacteria is a promising, natural and effective method.  Furthermore, if 
probiotics could be used in this way instead of antibiotics, the intestinal flora would be 
augmented instead of destroyed, providing significant health benefits beyond the 
immediate treatment of infection. 
Experiments involving binding between B. bifidum and L. reuteri (Mukai et al. 
2004) have shown that protein-comprised entities of bacterial cell surfaces can attach to 
the carbohydrate portions of glycolipids in the intestinal tract.  The affinity displayed by 
the bacteria for these glycolipids may be significant in establishing their residency in the 
intestine.  Some probiotic bacteria also seem to share a specific carbohydrate binding 
manner with enteropathogenic bacteria, however the early presence of the probiotic 
bacteria may hinder colonization and thus infection by the pathogenic ones (Mukai et al. 
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2004).  For example, in one experiment (Mukai et al. 2002), Lactobacillus reuteri was 
used in a competitive binding assay with Helicobacter pylori, the bacterium associated 
with causing stomach ulcers.  The two strains of L. reuteri in this assay effectively 
prevented binding of H. pylori by binding to the same glycolipid receptors for which they 
have an affinity.  This is an exciting discovery, showing that certain strains of L. reuteri 
may prevent gastric infections with H. pylori. 
 
2.3  Techniques for analysis of bioactives 
 2.3.1  Bacterial binding 
 Due to the abundance of research that has revealed some of the incredible health 
benefits of probiotic bacteria, it naturally follows that further research would be carried 
out to elucidate the actual mechanisms of their actions.  Results from this could improve 
understanding of how to process and deliver these bacteria to the body for optimal 
benefits.  Studies involving bacterial binding have been carried out in tissue cultures as 
well as other non-tissue surfaces.  For instance, radioactive labeling of bacteria has been 
applied in assessing mucin binding.  Tagging bacteria in this manner allows visualization 
of adhesion to proteins or glycoproteins that are already attached to a surface (Tuomola et 
al. 2000).  Other methods of bacterial labeling include biotinylation with subsequent 
colorimetric reactions with conjugated molecules such as avidin-HRP (Rojas and 
Conway 2001).  Another possible means of evaluating binding is through Western 
blotting.  This can be accomplished by first separating bacterial cell wall proteins by 
polyacrylamide gel electrophoresis (PAGE), then electrophoretically transferring them to 
a membrane such as polyvinylidene difluoride (PVDF).  Radiolabeled mucin probes can 
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then be incubated with the membrane and their subsequent illumination of specific 
protein bands can reveal binding affinities (Ryan et al. 2001). 
 Other techniques to measure bacterial binding include DNA quantification, 
confocal laser scanning microscopy (CLSM), and optical laser tweezers.  For DNA 
quantification, the following protocol can be used.  Bacteria are first allowed to incubate 
with various dairy products, then separated through a sucrose density gradient (SDG), 
after which the unbound bacteria layer is recovered and the DNA extracted and 
quantified.  After using spectroscopy to determine the amount of unbound bacteria, a 
simple calculation can be used to find the remaining quantity of bacteria that theoretically 
bound to the dairy products.  A second approach to evaluating binding is CLSM, which 
allows direct visualization of this interaction.  The bacteria and dairy products are 
fluorescently labeled with different stains, then incubated together and visualized with 
confocal microscopy (Figure 2.3).  In addition to providing an image of binding, this 
technique makes it possible to determine the binding location of the bacteria to the dairy 
product components.  A final method utilized by this research group is optical laser 
tweezers.  After incubating certain bacteria and dairy products together, they are 
visualized under an inverted microscope, upon which they are moved into a special 
optical trap where the milk fat globule is forced against the bacteria to induce binding.  
Once this occurs, the binding strength can be measured by a calculation resulting from 
the amount of force necessary to pull the bound complex apart using laser tweezers 
(Brisson et al. 2010).  The aforementioned methods represent promising and varied 
approaches of measuring bacterial binding for future research as well. 
 Figure 2.3:  Bacterial binding with MFGM.  
acidophilus (NCFM slpA) (stained in green) 
Imaging by confocal laser scanning 
 
 Another medium that has been used to evaluate bacterial binding is thin
chromatography (TLC).  TLC has been used for this purpose by incubating biotinylated 
lactic acid bacteria with a TLC plate pre
developing the plate colorimetrically, densitometric analysis was performed to measur
the binding specificity of bacteria for various glycolipids 
of this method is TLC blotting.  One research group used this to analyze binding of 
bacteria to glycosphingolipids.  The lipids were first separated by TLC, then transferred 
to a PVDF membrane, which was allowed to incubate with radioa
Escherichia coli.  Subsequent bioimaging showed binding to specific glycosphingolipids 
(Taki and Ishikawa 1997).  Other researchers have applied TL
immunological investigations, including quantification of antibody binding to cholesterol 
(Aniagolu et al. 1995), and binding of certain genes to gangliosides associated with brain 
tumors (Hamasaki et al. 1999
sloughing off of silica gel from the plate during treatments.  However, advantages of TLC 
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include its relative simplicity and short completion time, as well as the ability to easily 
separate mixtures of lipids and assess binding to each entity. 
 2.3.2  Immunoglobulin quantification 
 Several methods exist to quantify immunoglobulins (Gapper et al. 2007).  Some 
of the immunochemical techniques include the enzyme-linked immunosorbent assay 
(ELISA) (Conesa et al. 2005), radial immunodiffusion (RID) (Elizondo-Salazar et al. 
2010), and nephelometric immunoassay (Collin et al. 2002).  ELISA techniques are 
extensively used for quantitative or qualitative detection of a variety of antigens.  The 
design of the assay (direct, indirect, sandwich) varies with the order in which the 
antibodies and antigen are added to the microplate.  For example, in the sandwich 
ELISA, anti-bovine IgG antibodies are bound to the microplate, then overlaid with 
samples and a secondary conjugated anti-bovine IgG antibody.  The sample IgG is then 
detected and quantified by a colorimetric reaction produced by the conjugate and an 
enzyme (e.g. HRP and OPD, respectively).  A standard curve allows interpolation of the 
sample IgG concentrations. 
Another popular immunochemical technique is RID, a simple but time-consuming 
assay that entails application of IgG samples to wells of an agarose gel already containing 
antibodies to IgG.  During incubation, the samples penetrate into the gel and form a 
precipitate with the antibodies that appears as a ring.  The ring diameter is then used to 
calculate the IgG concentration based on results from IgG standards.  This method is 
reported to have poor precision, however (Fleenor and Stott 1981).  Nephelometry is a 
technique that measures the turbidity of the antigen-antibody complex formed in dilute 
colostrum or milk when anti-IgG1 is introduced to the solution.  The increase in light 
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scattering produced by this complex is proportional to the original concentration of IgG1 
in the sample (Collin et al. 2002).  An additional method that is very simplistic is 
hydrometry, which estimates immunoglobulin concentration by the specific gravity of the 
colostrum.  This physical technique is not very accurate, however, and is generally 
limited to use in field settings (Fleenor and Stott 1980). 
More sophisticated approaches also exist, such as an immunoassay read by direct 
biosensor surface-plasmon resonance (SPR).  The sample containing the desired antigen 
is allowed to flow over a biosensor surface covered with a covalently attached ligand, 
such as an antibody specific to IgG.  After a specified time period, the sample is removed 
from the surface.  This method works by sensing changes in refractive index due to the 
binding occurring on the biosensor surface.  Advantages of SPR are its high specificity 
and sensitivity for low concentrations of proteins.  The data obtained has been found 
comparable with RID and nephelometric methods (Gapper et al. 2007).   
Separation techniques, including various types of chromatography and 
electrophoresis, are also applied to the elucidation of immunoglobulin concentration and 
bioactivity, some of which include affinity chromatography and capillary electrophoresis.  
The immunochemical approaches, however, were the focus of this review due to the use 
of ELISA in the research that follows.  The above-reviewed methods may be used in 
experimental research or to satisfy requirements presented by quality control, regulatory 
compliance, food safety, and clinical or nutritional studies.  The selection of technique 
simply depends on the purpose of the data.  SPR and ELISA remain among the most 
precise and sensitive methods, however, and ELISA the more prevalent of the two 
(Gapper et al. 2007). 
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 2.3.3  HPLC analysis of phospholipids 
 Phospholipids can be separated and quantified by a few different methods, 
including thin-layer chromatography (TLC) and High Pressure Liquid Chromatography 
(HPLC).  TLC is a relatively fast, inexpensive method to separate lipids, though the 
densitometric quantification thereof is less precise than methods such as HPLC, thus it is 
mainly used for qualitative analysis.  Many HPLC methods have been developed.  One of 
the best thus far for both polar lipid separation and protection of column life is that 
developed by Rombaut et al. (2005).  This protocol uses a silica column with elution 
buffer containing a gradient of chloroform, methanol, and formic acid-triethylamine at 
pH 3.  Use of an evaporative light scattering detector (ELSD) with the HPLC system in 
this method results in excellent separation of polar and non-polar lipids from milk (Figure 
2.4) (Rombaut and Dewettinck 2006).  Once compared to chromatograms of lipid 
standards of known concentration, experimental lipid mixtures can be quantified.  HPLC 
lends itself especially well to the production of phospholipid extracts for application in 




Figure 2.4:  HPLC chromatogram of milk phospholipid extract.  Shows separation of 
polar lipids by the method of Rombaut et al. (2005).  NL= neutral lipids, GluCer: 
glucosylceramide; LacCer: lactosylceramide; PE; phosphatidylethanolamine; PI: 




2.4  Justification for this work 
 Given the abundance of studies showing the health benefits of probiotic bacteria, 
as well as the consumer demand for functional foods, it has become necessary to justify 
these effects with innovative research.  Thus far, studies surrounding the topic of 
probiotic delivery to the human body have been largely insufficient.  More definitive 
studies are needed regarding the interactions of probiotic bacteria with the various 
components of food matrices, including proteins, lipids, and carbohydrates.  These 
discoveries could provide insight into ways to carry these interrelationships from the food 
product to the gastrointestinal tract in hopes of exceptional viability and inhabitation.  
Due to the many studies that confirm the successful growth of probiotic bacteria in dairy 
products, it is logical to investigate their specific interactions with the assortment of 
elements in milk.  Understanding the associations of probiotics in their preferred 
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environment will likely provide important information that could be applied to the 
informed development of food delivery systems.  This knowledge, coupled with that of 
colonization mechanisms in the human gastrointestinal tract, could result in great 
advances in the development of functional food products that would ensure optimal 
benefits to human health. 
 In this thesis, some of the highly bioactive components of dairy products were 
studied to elucidate interactions among them and to apply their dairy ingredient sources 
to the development of a bioactive-rich food product.  Specifically, a novel technique was 
created that can measure the binding affinity of probiotic lactic acid bacteria for milk 
phospholipids.  Previous research has been completed on the binding of probiotic bacteria 
to proteins (e.g. mucins), but very little has been conducted with their adhesion to lipids.  
The lipid-binding method resulting from this work could be used to generate a library of 
information about the binding capabilities of various probiotic bacteria with lipid sources 
from food.  In addition to the designing the binding method, a dairy-based food product 
was developed as a means to deliver dairy bioactives such as immunoglobulins, 
phospholipids, whey proteins, and probiotic lactic acid bacteria.  It serves as an 
illustration of the successful use of these dairy ingredients in creating a high-value 
product.  As previously mentioned, the knowledge gained from bacterial binding studies 
could promote the development of highly bioactive functional foods, and serve to exploit 
the inherent health-enhancing properties of both probiotic bacteria and dairy products. 
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3.0  Materials and Methods 
3.1  Development of a method to measure binding between lactic acid bacteria and 
phospholipids 
3.1.1  Creation of parent and working stocks of lactic acid bacteria 
 Four strains of Lactobacillus were selected to be used in this research based on 
their probiotic properties (Table 3.1).  To create parent and working stocks, frozen 
cultures from the DPTC library were minimally thawed and 30 µl aliquots were 
inoculated into Man-Rogosa-Sharpe (MRS) broth (cat #288130, Difco Laboratories, 
Sparks, MD) enriched with 0.05% L-cysteine HCl (cat #BP376-100, Fisher Sci.).  
Cultures were grown overnight (approx. 18 hours) in an incubator at 37°C with 9.0% 
CO2 (Isotemp incubator, Fisher Sci.).  The next day, a heat-sterilized wire loop was used 
to streak each culture suspension in duplicate onto MRS + 0.05% cysteine agar plates, 
which were grown in an anaerobic chamber (BBL GasPak Plus, cat #271040, BD, 
Sparks, MD) for 48 hours at 37°C.  Plates were assessed for purity by the consistency of 
the colony size, shape, and color.  Then one or two colonies were selected, streaked 
heavily onto two fresh MRS agar plates, and grown at 37ºC for 48 hours.  Two mL of a 
sterile solution of 20% glycerol (cat #G33-1, Fisher Sci.) in MRS broth + 0.05% cysteine 
was added to each plate and gently mixed into a solution with the bacterial colonies using 
a sterile plastic loop (cat #22-363-597, Fisher Sci.).  The suspension was pipetted into 
sterile 1.0 mL cryogenic vials (cat #5000-0012, Nalge Co., Rochester, NY) and frozen at 




Table 3.1.  Lactobacillus species and applications 
Common Name Scientific Name Experiment(s) 
NCFM L. acidophilus Colorimetric & fluorescent dots 
TLC 
Blotted membranes 
SD2112 L. reuteri Colorimetric & fluorescent dots 
TLC 
Blotted membranes 
T-1 L. reuteri Fluorescent dots 
Blotted membranes 
LC-10 L. casei Colorimetric & fluorescent dots 
TLC 
1063-S L. reuteri TLC 
Blotted membranes 
700396 L. acidophilus Blotted membranes 
23272 L. reuteri Blotted membranes 
33199 L. gallinarum Blotted membranes 
53103 L. rhamnosus Blotted membranes 
 
 For later use in experiments, 30 µl of minimally thawed frozen bacterial working 
stock was inoculated into 10 mL of MRS + 0.05% cysteine broth and allowed to grow 
overnight (approx. 18 hours) while rotating at 37°C and 9.0% CO2.  The next day, 100 µl 
of freshly grown bacterial suspension was inoculated into 10 mL of new MRS + 0.05% 
cysteine broth and grown overnight as before.  This subculture was stored at 4°C and 
used as working stock for future research. 
The growth of each strain of bacteria was studied during 18 hours to determine 
the optical density corresponding to mid-log phase, the stage at which the bacteria would 
be used for experiments.  To complete this, 1 mL of working stock (subcultured twice 
from frozen stock) was inoculated into 100 mL of sterile MRS broth and incubated at 
37°C.  Every 30-60 minutes, each 100 mL flask containing bacteria was swirled gently to 
mix, then 2 mL was transferred to a 4.5 mL cuvette (PMMA, cat #89047-230, VWR Intl, 
West Chester, PA), and the optical density was read at 600 nm using a spectrophotometer 
(SpectraMax Plus, Molecular Devices, Sunnyvale, CA).  Based on this study, to make 
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new culture for experiments, 100 µl of working stock was added to 10 mL fresh MRS + 
0.05% cysteine broth and grown at 37°C to the same OD at 600 nm, which was 
approximately 7 hours for mid-log phase. 
3.1.2  Blotted membrane trials 
 The first experiments to assess bacterial binding to phospholipids involved blotted 
membranes.  A working stock of each strain of lactic acid bacteria (Table 3.1) was made 
by inoculating 100 µl of DPTC library working stocks (in use by Guillaume Brisson) into 
10 mL fresh MRS + 0.05% cysteine broth.  Bacterial growth phases had not yet been 
studied, so cultures were grown overnight (about 18 hours) at 37ºC, then stored at 4ºC.  
For experimentation, cultures were made by inoculating 100 µl of the refrigerated 
working stock into 10 mL MRS broth and incubating at 37ºC for about 18 hours.  The 
bacteria were centrifuged at 3200xg for 5 minutes to form pellets (Eppendorf 5810R), 
then reconstituted in 10 mL of 1x phosphate buffered saline (PBS) buffer pH 7.2 
(Appendix G), and washed 3 times by centrifugation.  Bacteria were diluted to OD600nm = 
1.0 ± 0.1, then biotinylated as follows.  For each strain dilution, 250 µl was transferred 
into 1.5 mL eppendorf tubes (cat #02-406-16, Fisher Sci.), and to each tube 50 µl of 10 
mM biotin solution (4.4 mg in 1 mL deionized water) (EZ-Link Sulfo-NHS Biotin, cat 
#21217, lot #IH112737, Pierce, Rockford, IL) and 50 µl of 700 mM α-lactose (in 
deionized water) (cat #L5-500, Fisher Sci.) was added.  Solutions were incubated at room 
temperature for 1 hour, then centrifuged at 3200xg for 5 minutes.  Resuspended pellets 
were washed twice in 1x PBS pH 7.2 to remove unbound biotin, and centrifuged at 
3200xg for 5 minutes between washes.  Washed pellets were resuspended in 1 mL PBS. 
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Strips of polyvinylidene difluoride (PVDF) (0.2µm pore, cat #1620184, lot 
#BR8183044, BioRad, Hercules, CA)  and nitrocellulose (NC) membranes (0.45µm pore, 
cat #88014, lot #DD71802, Pierce, Rockford, IL) were cut to 2x8 cm and soaked in 70% 
isopropanol for 30 minutes.  They were dried between sheets of filter paper (size #1, cat 
#1001917, Whatman, NJ), then blotted with 3 µl of phospholipid standards (PC, PE, PI, 
PS, SM) (Table 3.2) at 0.4 mg/ml in 2:1 CHCl3:MeOH (cat #C606-4 & #A452-4, Fisher 
Sci.), and allowed to dry for 20 minutes.  Strips were blocked in a solution of 1.5% 
porcine gelatin (cat #G8-500, lot #954220A, Fisher Sci.) for 20 minutes at room 
temperature, then washed 3 times in 1x PBS pH 7.2.  Each tube of washed, biotinylated 
bacteria (1 mL, from above) was added to 15 mL of 1x PBS pH 7.2 in a 50 mL falcon 
tube, and to each tube one dried, phospholipid-blotted membrane strip was added.  Tubes 
were incubated overnight (about 18 hours) in an incubator at 37ºC while gently shaking.   
The next day, strips were washed 3 times in 1x PBS pH 7.2, then divided between 
two small tupperware containers according to the type of bacteria.  They were separated 
in case of cross-contamination from unbound bacteria as well as to ensure that the strip 
surfaces were fully covered and not prevented from streptavidin attachment due to 
sticking together.  Each tub of two strips was incubated with 15 µl streptavidin-HRP 
(1mg/mL stock, cat #31001, lot #HG105020, Pierce, Rockford, IL) and 30 mL 1x PBS 
pH 7.2 (1/2000 dilution) for 2 hours at room temperature while gently shaking.  Strips 
were washed 3 times as before, then divided among four small tupperware containers.  
This allowed the strips to be fully covered by the next treatment, rather than sticking 
together.  A 0.6 mg/ml color-developing solution was made of 36 mg 3,3’-
diaminobenzidine tetrahydrochloride (DAB) (cat #D5637, lot #027K37251, Sigma-
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Aldrich), 75 µl hydrogen peroxide (30% w/w, cat #H1009, Sigma-Aldrich), and 60 mL 
1x PBS pH 7.2, and divided among the strips.  While agitating, strips were allowed to 
react for 5 minutes with the DAB solution, then rinsed once in DI water and dried 
between filter paper.  The process for this procedure can be seen visually in Figure 3.1.  
Strips were not quantitatively studied due to lack of proper equipment (e.g. a 
densitometer).  The results were visually inconsistent among trials, and the 
reproducibility of the method seemed low. 
Similar trials to the above were also done with fluorescent streptavidin (1mg/mL 
stock, AlexaFluor488, cat #S11249, lot #449352, Invitrogen) in substitution for HRP-
conjugated streptavidin.  This protocol used the same 1/2000 dilution of streptavidin in 
PBS, but once added to the strips, they were protected from light by aluminum foil, and 
analysis was attempted using a GelDoc (BioRad, Hercules, CA), although not the ideal 
piece of equipment (e.g. densitometer).  However, quantitative analysis was still 
inconsistent among trials and questionable, and visual results were inconsistent. 
  
 Figure 3.1.  Illustration of blotted membrane method.
(A) preparation of biotinylated bacteria, (B) attachment of the bacteria to the 
phospholipid-coated PVDF membrane, and (C) color deve
 
 







Phospholipid concentrate 700 
Cyper FP11 (PL mix) 
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  Summary of method that shows 
lopment to reveal 
 
Source Company Experiment(s)
Egg yolk Sigma (P3556) All 
 Egg yolk Sigma (P7943) Blotted membranes
Colorimetric dots
TLC 
Bovine brain Sigma (P9763) Blotted membranes
Colorimetric dots
TLC 
Bovine brain Sigma (P7769) Blotted membranes
Colorimetric dots
TLC 
Bovine brain Sigma (S7004) All 


















3.1.3  Thin-layer chromatography (TLC) trials 
This method was adapted from thesis experiments by Dee Bachiero (Bachiero et 
al. 2007), and based on her results, seemed to be a promising alternative to the blotted 
membrane method.  The procedure can be visualized in Figure 3.2.  A glass thin-layer 
chromatography tank (Kontes Glass Co., NJ) was lined with filter paper (size #1, cat 
#1001917, Whatman, NJ) around the sides, and a mixture of solvents was added to the 
tank (65:25:4 mL chloroform:methanol:water; cat #C606-4, cat # A45204, Fisher Sci.).  
The solvents were allowed to travel up the filter paper for 20 minutes.  Meanwhile 12 µl 
of each phospholipid standard (each at equimolar concentrations of 5x10-9
 
M) (Table 3.2) 
was applied with a capillary tube equidistantly along a line 3 cm from the bottom of a 
silica gel glass plate (60 Å, 250µm layer, cat #4860-720, Whatman, NJ).  The plate was 
allowed to dry for 10 minutes, placed in the tank, and allowed to sit until the solvents 
traveled to 1 cm from the top of the plate.  The plate was removed from the tank and 
allowed to dry in a vacuum oven at 80ºC for 10 minutes.  The method used to prepare the 
plates for bacterial binding was adapted from Mukai (2004).  To fix lipids to the plate, it 
was dipped in hexane (cat #H302, Fisher Sci.) for 1 minute, and then a polymer coating 
for 1 minute.  The coating solution was made by preparing a 10% (w/v) solution of 
poly(isobutyl methacrylate) (PIBM, cat #181544, Sigma-Aldrich) in chloroform, then 
diluting this 1/100 in hexane for a 1 mg/ml stock, which was diluted 1/10 with hexane 
just before use.  The plate was blocked in 1% fish gelatin (cat #G7041, Sigma-Aldrich) in 
PBS for 2 hours, washed 3 times in PBS, then incubated overnight with 2 mL 
biotinylated bacteria (at OD600nm = 2.0) (Table 3.1) in fresh 1% fish gelatin in PBS 
 (bacterial preparation same as in blotted membrane trials).
overnight (approximately 18 hours) at 37
The next day, the plate was incubated with
(1 mg/ml stock, cat #31001, lot #HG105020, Pierce, Rockford
then washed and developed with DAB.
membrane trials, using 36 mg 
pH 7.2.  The plate was allowed to react for 5 minutes with the DAB solution
washed once in PBS and allowed to dry overnight. 
GelDoc.  However, the method w
sloughed off of random parts of 
did not meet the desired consistency and seemed questionable.
Figure 3.2.  Illustration of TLC method.  Summary of method that shows (A) lipid 
separation on TLC plate, (B) attachment of biotinylated bacteria to the phospholipid
coated TLC plate, and (C) color development to show binding.
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  The plate was incubated 
ºC and 9% CO2. 
 a 1/2000 dilution of neutravidin
, IL) in PBS for 2 hours, 
  DAB developer was made as in blotted 
DAB, 75 µl 30% hydrogen peroxide, and 60 mL 1x PBS 
,
 The dried plate was analyzed with the 
as not conducive to good reproducibility (e.g.










3.1.4  HPLC analysis of phospholipids 
For subsequent binding trials, a phospholipid mixture (PL mix) derived from milk 
was used (Table 3.2).  Analysis of the PL mix was carried out to verify its composition.  
The phospholipid separation was performed by high performance liquid chromatography 
(HPLC; Hitachi HPLC System D-7000) combined with a charged aerosol detector (CAD) 
(Dionex) according to the methodology described by Rombaut et al. (2005).  Nitrogen 
was used as a carrier gas at a backpressure of 2.4 bar.  A 150 mm x 3.0 mm Prevail™ 
silica column with a 3 µm particle diameter (cat #99341, Grace Davison) was used.  A 
precolumn with the same packing, a length of 7.5 mm, a 3.0 mm internal diameter, and 5 
µm particle diameter was also used (cat #99354, Grace Davison).  The samples and the 
column were equilibrated at 40°C, and the flow was maintained at 0.5 mL/min.  The 
injections consisted of volume was 20 µl and the injection loop was rinsed with 
chloroform/methanol (2:1 v/v) between injections.  The phospholipid standards analyzed 
were phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, 
phosphatidylserine, and sphingomyelin (Table 3.2) (Sigma-Aldrich).  The PL mix sample 
was diluted to 0.75 mg/ml in 2:1 chloroform/methanol.  The phospholipid elution was 
performed with a linear gradient and 87.5: 12: 0.5 (v/v/v) 
chloroform/methanol/triethylamine(TEA) buffer (pH 3.0, 1M formic acid) at t = 0 
minutes (ACS grade TEA, all others HPLC grade, Fisher Sci.).  At t = 16 minutes, the 
mobile phase was 100% eluent B (28: 60: 12, v/v/v).  The mobile phase was brought back 
to 100% eluent A at t = 17 minutes, and the column was equilibrated until the next 
injection at 28 minutes.  Samples and standards were run in triplicate, and the collected 
data was analyzed using PowerChrom (eDAQ) and Excel 2007. 
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3.1.5  Colorimetric dot trials 
 After concluding that TLC was not a reliable method for assessing bacterial 
binding, a modification of the blotted membrane trials was made utilizing dots.  A 
summary of the method is illustrated in Figure 3.3.  A standard hole punch was used to 
create equally sized circles of polyvinylidene difluoride membrane (PVDF) (0.2µm pore, 
cat #1620184, lot #BR8183044, BioRad, Hercules, CA) as a medium for binding.  Dots 
were placed in 0.6 mL eppendorf tubes, and to each tube 100 µl of phospholipid 
standards or phospholipid mix at 2.5 mg/ml was added and allowed to incubate for 45 
minutes.  Samples included PC, PE, PI, PS, SM, and PL mix (Table 3.2), and the diluent, 
2:1 chloroform:methanol, was used as a control.  Various levels of phospholipid were 
evaluated, ranging from 0.15 to 2.5 mg/ml, and 2.5 mg/ml produced the most even color 
on the circles.  Phospholipids were removed by pipeting, then dots were vacufuged for 10 
minutes.  After initial trials showing high background color on control dots, a blocking 
step was added consisting of submersion of each dot in 100 µl 1% fish gelatin in PBS for 
1 hour.  Dots were then washed 3 times in 100 µl PBS.  Lactic acid bacteria (Table 3.1) 
were washed and biotinylated by the same method as in blotted membrane trials, and   
100 µl was added to each tube (OD600nm = 2.0).  Dots were incubated overnight 
(approximately 18 hours) at 37ºC.   
 The next day, dots were washed 3 times in PBS, then incubated for 1 hour with 
100 µl of 1/2000 neutravidin-HRP (1 mg/ml stock) in PBS.  The dots were washed 3 
times in PBS, and then DAB color-developing solution was added and allowed to 
incubate for 15 minutes.  DAB developer (0.6 mg/ml) was made as in blotted membrane 
trials, but using 8 mg DAB, 17 µl 30% hydrogen peroxide, and 11 mL 1x PBS pH 7.2.  
 After incubation, the dots were rinsed with PBS, then dried between filter paper and 
affixed to fresh filter paper with clear tape.
quantitative analysis was not performed because a densitometer was not avail
the results were visually inconsistent anyway, so the method was abandoned.
 
Figure 3.3.  Illustration of colorimetric dot method.  Summary showing (A) preparation 
of phospholipid-coated PVDF dots, attachment of biotinylated bacteria to the 
phospholipid-coated dots, and (C) color development to show binding.
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3.1.6  Fluorescent dot trials 
Upon the conclusion that a colorimetric method was not feasible for assessing 
bacterial binding, a modified method using fluorescence was created (also illustrated in 
Figure 3.4).  Dots of Immobilon PVDF transfer membrane (0.45µm pore, cat 
#IPVH00010, lot #K7PN6216A, Millipore, Bedford, MA) were again made with a 
standard hole punch, then placed in 0.6 mL eppendorf tubes.  To each tube, 100µl of 
phospholipid (PL) standards (PC & SM) and a PL mixture (from milk), all at 12 mg/ml, 
was added (Table 3.2).  CHCl3 / MeOH (2:1) was included as a negative control, and 
canola oil (also at 12 mg/ml dissolved in the control solvents) was added to compare 
binding to triglycerides.  Preliminary trials included testing a range of ten PL 
concentrations from 0.75 mg/ml to 12 mg/ml, and 12 mg/ml resulted in the most 
complete coverage of the membrane. Dots were incubated for 10 minutes, then lipids 
were removed by pipetting and the tubes were vacufuged for 10 minutes to dry 
(Eppendorf vacufuge).  Lactic acid bacteria (Table 3.1) were grown at 37ºC (with 
rotation) to their respective optical densities (600nm) for mid-log phase (approximately 7 
hours) (LC10: 1.463, NCFM: 0.975, SD2112: 1.696, T-1: 1.743) (Appendix A).  They 
were then washed in 0.05M Tris pH 7.2 and diluted to OD600 nm = 1.0.  One mL of each 
strain was incubated for 5 minutes with 1 µl acridine orange (stock at 10mg/mL, cat 
#A8097, lot #117K1207, Sigma-Aldrich) while protected from light.  Bacteria were 
centrifuged at 960xg for 6 minutes to pellet, and then the pellets were reconstituted and 
washed twice in 1 mL 0.05M Tris pH 7.2.  To each dry PL dot, 100 µl of prepared 
bacteria was added and dots were allowed to incubate for 20 minutes in the dark.  Initial 
experiments included comparison of binding with four levels of bacteria, consisting of 
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dilutions of 25%, 50%, and 75% of the final one used.  The highest dilution resulted in 
the most even binding, thus was used for future experiments.  To assess non-specific 
fluorescing of the stained bacteria and each of the lipids and control, dots were also made 
after incubation solely with each of these.  After exposure to the fluorescent bacteria, dots 
were rinsed in 0.05M Tris pH 7.2, dried between filter paper, then affixed with clear tape 
to a glass plate and covered with foil.  Each combination of PL and bacterial strain was 
tested in duplicate and repeated for four trials.  The fluorescence was analyzed with the 
Typhoon Trio+ variable mode imager (serial #98115, Amersham Biosciences). 
The Typhoon was allowed to warm up for 5 minutes, and the following scanning 
parameters were selected:  fluorescence acquisition mode, 526 SP Fluorescein Cy2 
AlexaFluor488 emission filter, 200 PMT, blue 488 laser, normal sensitivity, 100 pixels, 
platen focal plane, and ImageQuant analysis.  The glass plate with dots attached was 
placed face down on the scanner.  Once scanning was complete, the file was saved in 
ImageQuant (Amersham Biosciences), and then FluorSep (Amersham Biosciences) was 
used to produce images showing the fluorescence.  The scan was then analyzed by 
ImageQuant TL (v. 2005) and the array analysis feature was used to measure the 
fluorescence intensity of circles (size 15 units radius) within each dot.  Raw data was then 
exported to Excel 2007 (Microsoft) for graphing and analyzed statistically in Minitab 16 
by Analysis of Variance General Linear Model and Tukey’s test. 
 Figure 3.4.  Illustration of fluorescent dot method.  
preparation of fluorescently-stained bacteria, and
phospholipid-coated PVDF dots
 
3.2  Development and analysis of
3.2.1  Formulation 
A dairy-based gel was formulated as an additional experiment to demonstrate the 
successful application of dairy ingredients in creating a highly nutritious food product.  
Included in this formulation were ingredients containing some 
bioactives found in dairy products
probiotic bacteria.  Other highly nutritious dairy ingredien
including whey proteins.  The formulation was as follows: whey protei
water, buttermilk powder (BMP)
starch, and lactic acid bacteria
water by allowing it to stir on a hot plate at 60
the raw colostrum by the same method
ingredients, except WPI, were
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Summary of method showing (A) 
 (B) attachment of the bacteria to the 
. 
 a dairy-based, bioactive-rich gel 
of the aforementioned 
, such as phospholipids, immunoglobulins,
ts were also integrated, 
n isolate (
, raw colostrum, sugar, agave nectar, modified food 
 (Table 3.3).  To create the gel, the WPI was dissolved in 
ºC for 1 hour.  The BMP was dissolved
.  The colostrum/BMP and the remaining 








added.  Once the mixture had cooled, the bacteria were added, and the gel was stored in a 
50 mL falcon tube at 4ºC.  Nutritional analysis was done with Genesis R&D software 
(ESHA Research), and is shown in Figure 4.13. 
 
Table 3.3.  Dairy-based gel formulation. 
Ingredient Source Quantity 
Colostrum – Super Lite Organic Pastures Dairy Co. LLC (Fresno, CA) 250 g 
Buttermilk Powder (UF/DF)  DPTC produced (2008) 25 g 
Whey Protein Isolate (WPI), 
BiPro, 98% 
Davisco Foods Intl (Eden Prairie, MN) 15 g 
Sucrose C&H – Domino Foods (Yonkers, NY) 15 g 
Agave nectar Madhava Honey Co. (Lyons, CO) 15 g 
Water (tap) - 100 g 
Salt Morton (Chicago, IL) 0.4 g 
MaxiGel Modified Food Starch 
445 
Tate & Lyle (Decatur, IL) 6 g 
Lactic acid bacteria- L. reuteri 
(SD2112) & L. acidophilus 
(NCFM) (pellets from 10 mL 
tubes) 




3.2.2  Analysis by ELISA 
A sandwich ELISA design was used to compare the quantity of immunoglobulin 
G (IgG) in commercial whole milk, commercial colostrum, and the aforementioned 
dairy-based gel.  A 96-well clear polystyrene plate (cat #125-65-501, Fisher Sci.) was 
coated with 100 µl primary antibody (anti-bovine IgG, whole molecule, polyclonal, 
produced in rabbit, cat #B5645, lot #096K4772, Sigma-Aldrich) at 2/1000 in 0.1M 
carbonate-bicarbonate pH 9.6 (Appendix G) and incubated for 1 hour.  For the remaining 
washing and dilutions, 1x TBS-Tween-20 pH 8.0 was used (Appendix G).  The plate was 
washed and samples were added in triplicate with milk at 2/10,000, and colostrum and 
gel at 2/100,000.  Lyophilized bovine IgG standard was reconstituted in 1x PBS pH 7.2 
(cat #I5506, lot #058K7675, Sigma-Aldrich) and added in duplicate at dilutions of 0, 7.8, 
15.6, 31.25, 62.5, 125, and 250 ng/mL to construct a standard curve.  The plate was 
incubated for 1 hour, then washed, and secondary antibody (anti-bovine IgG, HRP 
conjugate, whole molecule, polyclonal, cat #A7414, lot #28H9245, Sigma-Aldrich) was 
added at a dilution of 5/10,000.  The plate was incubated for 1 hour, washed, and 100 µl 
o-phenylenediamine dihydrochloride (OPD) solution (cat #P6787, Sigma-Aldrich) was 
added to each well.  OPD solution was prepared by dissolving 4 mg OPD in 10 mL 
0.05M citrate-phosphate pH 5.0 (Appendix G) and 10 µl 30% hydrogen peroxide.  The 
plate was incubated for 20 minutes, then 50 µl of 2M H2SO4 (cat # A300S-212, Fisher 
Sci.) was added to wells to stop the reaction.  After 5 minutes, the plate was read at 
492nm, using a spectrophotometer and SoftMax Pro (Molecular Devices), then data was 
analyzed using Excel 2007 (Microsoft) and Minitab 16. 
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4.0  Results 
4.1  Bacterial binding with phospholipids 
4.1.1  Bacterial growth studies 
 There were four strains of Lactobacillus used in the final binding experiments, 
including two types of L. reuteri (SD2112 and T-1), L. acidophilus (NCFM), and L. casei 
(LC-10) (Table 3.1).  As previously mentioned, upon assuring purity by streak plate 
morphology and preparing frozen stock, each strain was subcultured and its growth was 
evaluated to determine the optical densities relating to mid-log phase.  Throughout the 
growth study, absorbance readings were taken with a spectrophotometer at 600 nm every 
30-60 minutes during a period of 18 hours, at which point a graphical representation 
showed that the bacteria had entered stationary phase of growth (Appendix A).  The 
resulting optical densities were plotted with time (Figure 4.1). 
 
Figure 4.1.  Lactobacillus growth over 18 hours. Initial inoculum 1/100 in MRS broth. 




























 4.1.2  Blotted membrane trials
 The blotted membrane tr
between Lactobacillus strains 
evaluated quantitatively due to lack of proper equipment
were also found to be visually inconsistent
minimally reproducible.  Photos were taken of the developed strips
 
Figure 4.2.  Colorimetric blotted membranes
different phospholipids, and strips represent different bacteria (in duplicate; both 
in Tables 3.1 & 3.2). 
 
 Trials with fluorescent streptavidin were 
with less background than the colorimetric experiments, but they were 
inconsistent and questionable results
GelDoc (BioRad, Hercules, CA)
 
Figure 4.3.  Fluorescent blotted membranes.  Spots represent different phospholipids, and 
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 4.1.3  TLC trials 
After the blotted membranes were 
bacterial binding to phospholipids was made using thin
plates as a medium.  Similar to the
with phospholipid standards, 
developed using neutravidin and DAB
(BioRad) (Figure 4.4). 
 
Figure 4.4.  TLC binding assay
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 4.1.4  Colorimetric dot trials
 After previous unsuccessful methods to measure bacterial binding, a modified 
approach to blotted membranes 
which were allowed to bind with triglycerides and phospholipids
1% fish gelatin.  Again, they were incubated with biotinylated lactic acid bacteria and
developed using neutravidin and
quantitatively due to lack of proper equipment 
The results were visually inconsistent among trials, and the reliability of the 
method seemed poor.  The method was discarded after this
discovery that biotinylated bacteria bound to the membrane by themselves (visually) 
equally well as when phospholipids were present, making the PL results false positives.  
Photos were taken of the developed dots (Figure 
Figure 4.5.  Colorimetric dot assay.  Controls included the solvents used to dilute the 
lipids (CHCl3:MeOH) and canola oil.  Dots were produced in duplicate, with and without 
addition of biotinylated lactic acid 
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4.1.5  Fluorescent dot trials 
 The method that finally produced successful results involved fluorescence.  Due 
to the apparent non-specific binding of biotinylated bacteria to the PVDF membrane in 
the previous method, a more simplistic approach was taken.  Bacteria were stained with 
acridine orange, a fluorescent dye, and allowed to bind to dots of membrane already 
incubated with phospholipids.  A Typhoon image scanner was used to analyze the 
fluorescence (raw data in Appendix B).  To assess non-specific fluorescing of stained 
bacteria and each of the lipids and control, dots were also made after incubation solely 
with each of these.  After exposure to the fluorescent bacteria, non-specific fluorescence 
values were comparable amongst dots of CHCl3:MeOH, PL only, and bacteria only. 
The results were statistically consistent among trials (p<0.05), and the reliability 
of the method was good.  In contrast to the previous colorimetric assay, the fluorescently 
stained bacteria exhibited very little non-specific binding to the membrane.  Images of the 
resulting dots were obtained with the Typhoon scanner and FluorSep program (Figure 
4.6).  Not shown are the dots from assessment of non-specific fluorescing of the bacteria 
and lipids.  These dots appeared black, thus none to very little non-specific fluorescence 





Figure 4.6.  Fluorescent dot assay.  Controls included the solvents used to dilute the lipids 
(CHCl3:MeOH) and canola oil.  Dots were produced in duplicate, all with addition of 
fluorescently-stained lactic acid bacteria (defined in Table 3.1).  All lipid concentrations 
were 12 mg/ml in 2:1 CHCl3:MeOH (defined in Table 3.2).  Colors shown are arbitrary. 
  






 4.1.5.1  Fluorescent dot trial statistical analysis
 The data resulting from the fluorescence trials 
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Table 4.1.  Fluorescent dots analyzed by Tukey’s test for comparison.  Entities with the 
same letter in the same column are not significantly different from each other (p<0.05).  
Lipids and bacteria are compared separately. 
 
Lipids Bacteria 
PL mix - A SD2112 - A 
PC  -  B LC10  -  A 
SM  - C T-1  -  A, B 


































































Normal Probability Plot Versus Fits
Histogram Versus Order
Residual Plots for Data
 
 
Figure 4.8.  Fluorescent dot residual plots.  This shows the distribution of binding data 
accompanying statistical analysis by Minitab 16. 
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4.2  HPLC analysis of phospholipids 
 A milk-derived extract of phospholipids (Table 3.2) was used in multiple binding 
trial experiments alongside individual phospholipid standards.  To assess its composition, 
high pressure liquid chromatography (HPLC) was used to separate the lipids.  The 
chromatogram is shown in Figure 4.9.  From the resulting data (Appendix C), the 
concentrations of each phospholipid in the phospholipid extract were calculated by 
interpolation from existing equations made from the analysis of phospholipid standards 
(Table 4.2). 
 
Figure 4.9.  Chromatogram from HPLC analysis of PL mixture.  NL = neutral lipids; 
LacCer = lactosylceramide; phospholipids = see table 4.2 below. 
 
 
Table 4.2.  Phospholipid concentrations in milk PL extract.  Upon analysis by HPLC, the 
percent composition of the phospholipid portion of the extract was calculated. 
Phospholipid % of total PL mix 
(by mass) 
Phosphatidylcholine (PC) 19.2% 
Phosphatidylethanolamine (PE) 18.6% 
Phosphatidylinositol (PI) 1.05% 
Phosphatidylserine (PS) 4.87% 
Sphingomyelin (SM) 23.8% 
  
Phospholipids Time (min) 








4.3  Dairy-based, bioactive-rich gel 
4.3.1  ELISA analysis of immunoglobulins 
 Upon creation of the colostrum-rich energy gel, the content of immunoglobulins 
was of interest.  An enzyme-linked immunosorbent assay (ELISA) protocol was 
developed to accomplish this.  A sandwich design was chosen and used to quantify 
immunoglobulin G (IgG) in commercial whole milk and colostrum in addition to the 
aforementioned dairy-based gel.  After completion of the assay (Figure 4.11), the 
absorbance data (Appendix D) were collected using the spectrophotometer and SoftMax 
Pro, and analyzed using Excel 2007 (Microsoft).  A standard curve (quadratic regression) 
was constructed from the absorbance values of the bovine IgG standard and used to 
determine the IgG concentration of each dairy sample (Figure 4.10; Table 4.3).  To verify 
consistency among trials, data (Appendix D) was analyzed using Minitab 16 (Appendix 
F).  A residual plot expressing the normalcy of the data follows (Figure 4.12). 
 
Figure 4.10.  Standard curve resulting from ELISA analysis of bovine IgG.  Quadratic 
regression curve fitted to absorbance values (492nm) plotted against concentration. 
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 Table 4.3.  Immunoglobulin G (IgG) concentrations
quadratic regression curve from the bovine IgG standards, IgG concentrations were 
calculated from the average respective absorbance values of the milk, colostrum, and gel 
samples.  Literature values for milk and colostrum are also shown
(Hurley 2003; Saito 2009). 







Figure 4.11.  ELISA plate after colorimetric development with OPD.  
columns 1-4 and rows A-D represent bovine IgG standards (increasing from left to right 
and top to bottom) (these are replicated in rows E































Figure 4.12.  Residual plots resulting from 
shows the distribution of bovine IgG absorbance
curve. This accompanied statistical analysis by Minitab 16.
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 4.3.2  Nutritional analysis of gel
 The ingredients for the dairy
R&D software, and the formulation was used to calculate the basic nutrition facts for a 
100 gram serving of the final energy gel.
the gel, the mass of water lost as steam was
the product obtained from the initial weight of all the ingredients.  
entered into Genesis reflects the water loss.
 
 
Figure 4.13.  Nutrition
analysis of gel by Genesis.




-based gel were added to the database in Genesis 
  It should be noted that upon heat processing of 
 calculated by subtracting the final weight of 
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Figure 4.14.  Finished colostrum






5.0  Discussion 
5.1  Bacterial binding with phospholipids 
5.1.1  Selection and growth of probiotics 
The purpose of studying the binding of lactic acid bacteria to phospholipids was 
to demonstrate both the presence of this interaction and to determine variations among 
Lactobacillus species and strains.  Lactobacillus reuteri, Lactobacillus acidophilus, and 
Lactobacillus casei were all selected due to their established identities as probiotics in 
human health and in food applications.  These bacteria were subjected to API (Analytical 
Profile Index, Biomérieux) analysis by previous researchers in our lab to affirm their 
identities.  In this research, their purity was affirmed by inspection of colony morphology 
and gram stains, and frozen and working stocks were maintained.  A growth study of 
each species was completed in order to find the length of time needed for each to 
proliferate to mid-log phase.  This stage of growth was selected as a means to support 
consistency in the physiological state of each bacterial strain when used for binding.  This 
is also a phase in which bacteria are highly metabolically active (e.g. enzyme activity and 
gene synthesis), thus it serves to mimic their dynamic in the intestine.  This state should 
induce bacterial receptivity to binding to surfaces for colonization, such as mucins or 
phospholipids, again making it ideal for the purposes of these experiments. 
5.1.2  Binding assays 
 The initial experiments performed to evaluate the binding interactions between 
lactic acid bacteria and phospholipids were not the most reproducible or reliable, but they 
served as necessary building-blocks to achieve the final method.  The principle behind all 
of the assays was to first allow a fixed concentration of phospholipids to attach to a 
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surface (e.g. PVDF membrane or TLC plate), and then expose them to equal quantities of 
chemically-labeled bacteria.  Labeling was a key component in producing distinct 
colorimetric or fluorescent results to indicate that binding had occurred.  These results 
then served as a measure of binding presence and frequency. 
5.1.2.1  Blotted membrane and TLC trials 
 PVDF membrane was an indispensable tool in many of the methods attempted.  In 
the blotted membrane trials, phospholipid standards were blotted in circles and 
biotinylated bacteria were allowed to incubate with the entire membrane.  One problem 
encountered was difficulty in applying the lipids to an even area on the membrane, but 
with the use of a plastic template this was improved.  Visually, the results from both 
colorimetric and fluorescent assays seemed promising because it was clear that binding 
was indeed occurring, however, they also appeared inconsistent and the necessary 
analytical equipment (e.g. densitometer) was unavailable to assess the true precision of 
this method.  Thin-layer chromatography (TLC) also appeared to be a feasible method, 
again based on the principle that biotinylated bacteria would attach to phospholipid 
standards separated on a TLC plate.  Unfortunately, a couple of factors hindered the 
ultimate use of this technique; namely, lack of consistency (visually) among trials, 
sloughing of silica from the plates, and lack of proper equipment to assess binding. 
5.1.2.2  Colorimetric dot trials 
A variation on the initial blotting method was initiated with the use of hole-
punched dots of PVDF membrane.  Also at this time, a phospholipid mixture was 
obtained and analyzed to verify its composition by HPLC, which showed results 
following a similar compositional pattern as that of other HPLC analyses of milk 
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phospholipid composition (Rombaut et al. 2005).  The calculated proportions of each 
phospholipid did not all precisely match those in the literature, however due to being 
from a unique extract concentrate (as opposed to milk), some variation seems reasonable.  
Also, due to the limited number of trials (n=3), additional analysis might produce results 
more consistent with those in the literature.  This mixture was used for all subsequent 
trials, having the advantage of providing a natural source of phospholipids extracted from 
milk.  Individual dots were incubated with the phospholipid standards, as well as the milk 
phospholipid extract, allowing more uniform distribution of the solvent and also 
providing a definite area on which to quantitatively measure binding.  At the outset, a 
similar system to the blotted membranes was employed, in that it involved the sequence 
of phospholipid binding, blocking with fish gelatin, and incubation with biotinylated 
bacteria, followed by the attachment of neutravidin-HRP and colorimetric development.  
An additional note about the blocking step is that fish gelatin was used due to studies that 
have shown superior blocking activity compared to porcine gelatin, bovine serum 
albumin, and casein in ELISA and Western blot applications (Vogt et al. 1987; Lee et al. 
1994).  Despite the theoretical success of this method’s organization, however, eventually 
the creation of certain controls led to the discovery of false positive results.  Color 
development was present to a similar visual extent in both blocked and unblocked PVDF 
dots that were not coated in phospholipids, but that were incubated in the presence of 
biotinylated bacteria.  The bacteria also exhibited affinity for dots only submersed in the 
control solvents, chloroform and methanol.  Thus it was surmised that by this assay, the 
bacteria also had confounding binding affinity for both the PVDF and fish gelatin 
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proteins.  Due to the lack of success at fixing this challenge, the mode of bacterial 
labeling was modified, and also simplified. 
5.1.2.3  Fluorescent dot trials 
 Fluorescent labeling of the bacteria proved to be the most successful means to 
assess binding.  In summary, all of the previous approaches showed that bacteria can 
indeed adhere to phospholipids attached to a membrane or surface, thus these same 
principles were carried forward in a manner that would prove reliable and quantifiable.  
In this last method, bacteria were simply stained with acridine orange and allowed to 
incubate with phospholipid-coated dots of PVDF.  Acridine orange stained the proteins of 
the bacteria, and provided a more direct means to report their presence than the use of 
biotinylation.  The buffer formulation was modified from PBS to Tris once this 
experiment began in order to eliminate the potential for nonspecific binding  of bacteria 
to the phosphate in PBS (since they have shown affinity for phospholipids in other 
research).  Another modification from previous methods was the use of bacterial dilutions 
at OD600nm = 1.0 instead of 2.0, in order to reduce potential variability in bacterial 
concentration due to spectrophotometric limitations.  Immediately upon completion of 
the experimental protocol, binding affinity was measured by fluorescence readings 
obtained from the Typhoon imaging scanner.  Fluorescence measurements for each 
bacterial species and the corresponding phospholipids and controls were then analyzed by 
Excel and Minitab for graphical and statistical comparisons.  The use of fluorescence to 
label the bacteria was advantageous in terms of its simplicity and production of results 
relatively quickly.  Disadvantages could potentially include induction of variation due to 
pipetting such a small volume of dye, as well as the possibility of not having well-
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calibrated this volume so as not to oversaturate the bacteria.  Also, it is conceivable that 
different bacteria may uptake the dye to different extents, depending on their cellular 
structure and reaction to growth conditions, which could drastically alter the 
representation of actual binding occurring.  Nonetheless, this proved to be the most 
reliable means of measuring binding in this series of experiments. 
For statistical analysis of the results, a General Linear Model (GLM) was used 
with fluorescence data as the response, and bacterial type, lipid, and trial as the model 
factors (Appendix E).  Tukey’s pairwise comparisons were made with the bacteria and 
lipids.  The results of the ANOVA and Tukey tests show that each of the four bacterial 
species exhibited minimal binding to the negative control (2:1 CHCl3:MeOH) and 
significantly less affinity for the positive control (canola oil triglycerides) than for all of 
the phospholipids included in the assay (p<0.05).  Certain phospholipids were preferred 
over others as shown by the significant differences in binding affinity to each (p<0.05).  
NCFM displayed significantly different binding than SD2112 and LC-10, but not T-1, 
and showed a tendency toward less (p<0.05).  There was no significant difference due to 
trial (p>0.05), which is also shown by the size of the error bars for the standard errors of 
the means (Figure 4.7).  Thus, in these experiments, binding events depended largely on 
the specific phospholipid or mixture thereof and somewhat on the bacterial strain.  From 
these findings, the questions arise as to why the bacteria preferentially bound to 




5.1.2.4  Interpretation of fluorescent binding results 
First, the very principles by which binding likely occurs must be reviewed.  Lactic 
acid bacteria are believed to attach to other molecules or surfaces primarily through 
interactions with their capsule, the region surrounding the cell wall.  Most notably for this 
discussion, in lactic acid bacteria this structural component may include anionic teichoic 
or lipoteichoic acids, but especially the S-layer proteins.  Bacterial attachment to 
phospholipids must involve the properties of the polar head group, given that this is the 
main distinction between these lipids and others with lower binding, such as triglycerides.  
To illustrate this, the arrangement of PL in the milk fat globule membrane (or any other 
cellular membrane for that matter) is such that the polar head groups face outward, and 
the nonpolar, hydrophobic FA chains face inward.  Since bacterial binding has been 
demonstrated with intact milk fat globules, it is logical to reason that the bacteria bind to 
the polar head group of the PL.  However, observations by other researchers that the 
more hydrophobic bacterial strains exhibit greater binding frequency complicate this 
conjecture.  These issues will be evaluated in the discussion that follows.   
While S-layer proteins are typically acidic (pI 4-6) in most bacteria, in lactic acid 
bacteria they are usually highly basic (pI >9.4) due to the greater proportion of positively 
charged amino acid residues.  These cationic residues (e.g. lysine and arginine) have been 
suggested to interact with lipid head groups possessing an anionic charge (Smit et al. 
2001).  In our experiments, the bacteria were diluted in Tris buffer at pH 7.2, which is 
very likely below the pI of their S-layer proteins, meaning that they would have a net 
positive charge under the conditions provided for binding.  Therefore, we can also 
propose that binding may be occurring between these positively charged amino acid 
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residues and any negatively charged portions of the phospholipid, including the 
phosphate group itself and the polar head group.  This could be occurring in the case of 
phosphatidylserine (PS) and phosphatidylinositol (PI) since both of these contain anionic 
polar head groups (Nelson and Cox 2000).  It can also be postulated from this that more 
binding interactions occur with increasing cationic properties imparted by a greater 
number of S-layer proteins. 
Thus, another explanation for the variance in binding affinity among strains of 
lactic acid bacteria may be differing proportions of S-layer proteins- the quantity has 
been shown to vary among strains and may directly impact binding.  Since the absence of 
S-layer proteins significantly hinders adhesive properties of lactic acid bacteria, their 
interactions with binding surfaces and molecules such as phospholipids are certainly 
worth exploring (Sillanpaa et al. 2000; Roos and Jonsson 2002; Frece et al. 2005).  The 
hydrophobicity imparted by S-layer proteins may explain why the more hydrophobic 
bacterial strains sometimes have greater binding affinity.  In binding experiments with 
environmental conditions of varying ionic strength, it has also been proposed that some 
lactobacilli without S-layers may have adaptable mechanisms to change their surface 
hydrophobicity, thus adapting to conditions in order to promote surface adhesion 
(Vadillo-Rodriguez et al. 2004).  This may explain binding events that occur with 
neutrally charged lipids, such as triglycerides.  Although S-layer proteins were not 
analyzed in our experiments, further study may show correlations in binding strength 
with S-layer protein proportions and cell surface hydrophobicity. 
Specifically examining the results of our research, a notable occurrence was the 
drastically lower binding exhibited by the bacteria for triglycerides than for all of the 
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phospholipids.  Previous research has found that binding to triglycerides is rather 
nonspecific compared to phospholipid binding, meaning that its occurrence is in more 
direct correlation with the concentration of lipid present.  In contrast, this publication also 
showed that bacterial binding affinity to phospholipids was specific to the strain rather 
than simply increasing with the concentration of lipid presented (Bachiero et al. 2007).  
The results of our experiments are compatible with these findings in that bacterial 
binding to equal concentrations of phospholipids and triglycerides was vastly different.  
Thus, hypothetically, if the concentration of triglyceride had been increased in these 
experiments, greater binding may have occurred.  This illustrates the exceptional 
properties possessed by phospholipids.  Also, the reasons for the preferential binding to 
phospholipids may be due to the presence of PL on cell surfaces.  Binding is a surface to 
surface interaction, thus it is logical that PL would be natural recipients of binding.  In 
contrast, triglycerides are not present on cell surfaces due to their hydrophobicity and 
structure, thus binding preference for them would theoretically be low, which is again 
clearly revealed in the results of these experiments. 
From our observations, it appears that providing a mixture of phospholipids to 
lactic acid bacteria is more advantageous to binding than providing isolated 
phospholipids.  It seems logical that the mixture would receive greater binding than its 
counterparts due to the possible synergy among phospholipids, as well as being a source 
of the complete range of milk lipids that the bacteria might coexist with had they been in 
this type of natural environment. It must be noted that this mixture does contain some 
non-polar lipids in addition to phospholipids, which may also account for some of the 
elevated binding affinity shown in this study.  Nonetheless, these results support the 
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notion that dairy products can provide excellent delivery of probiotics.  Given that it 
contains preferred molecules on which to adhere, the dairy system components 
theoretically result in better probiotic colonization in the product, as well as 
transportation of a higher proportion of viable microorganisms to the host. 
The phospholipid standards phosphatidylcholine (PC) (from egg yolk) and 
sphingomyelin (SM) (from bovine brain) used in these studies were also shown to have 
significant binding with the bacteria.  Being from non-milk sources, these results show 
that bacteria may adhere to any individual phospholipids, and also may help indicate the 
location of binding.  PC and SM have similar structural characteristics, and also share a 
net neutral charge on their polar head group (both contain identically structured 
phosphatidylcholine and phosphocholine, respectively), although this group contains 
positively charged amino acid residues.  Given that these polar lipids share the same 
polar head group, the question arises as to why binding data would significantly differ.  It 
may be that with more trials, this difference would become insignificant, but it is also 
possible that this variation is due to the dissimilarities of their structural backbones, 
glycerol and sphingosine.  The specific reasons behind this are not definitely known.  
Previously it was noted that binding may occur between positively charged amino acid 
residues of S-layer proteins and negatively charged portions of the polar lipid heads.  If 
that same principle did not apply in the case of PC and SM (only containing the anionic 
phosphate group), it may be that binding can also occur between the positively charged 
polar head and any anionic amino acid residues of the S-layer proteins, although present 
in lower proportions than the cationic ones (Nelson and Cox 2000).  However, the best 
explanation for the binding preference to SM as opposed to PC is the glycosylated nature 
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of SM, which is aptly classified as a glycolipid.  Glycolipids, which also include the 
mucins of the intestinal lining, are common cell-surface receptors, while phospholipids 
are situated in the cell membrane bilayer.  Thus, structurally it is logical that binding 
would naturally occur more frequently to SM than PC due to its structure and location. 
Given the complexity of biological systems such those studied here, it seems 
logical that there is actually an interplay of factors that result in binding interactions 
between lactic acid bacteria and phospholipids.  These may include the aforementioned 
structural properties of lactic acid bacteria, as well as the aspects of environmental 
conditions, which are likely to be crucial.  As demonstrated by these experiments, 
however, dairy systems can provide components essential to ensuring better probiotic 
colonization in the product, as well as deliverance of an increased number of functional 
microorganisms to the gastrointestinal tract.  As of now, there is no definitive explanation 
for why and how these associations occur, however, this study and others have at least 
shown their existence.  Also, due to the relatively limited direct research performed thus 
far on these microscale interactions, the work we have done will perhaps inspire further 
curiosity to explore and elucidate the details within. 
5.2  Formulation and analysis of a dairy-based, bioactive-rich gel 
 The dairy-based gel was created to demonstrate the successful application of 
ingredients with high bioactivity in a form with the potential for use as a nutritional 
supplement in the realms of sports nutrition or clinical applications.  Some of the major, 
bioactive-rich dairy ingredients—namely colostrum, buttermilk powder, and whey 
protein isolate—were indeed effectively integrated into a gel-like food product containing 
bioactives such as immunoglobulins, phospholipids, and whey proteins, as well as 
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probiotic bacteria.  Colostrum was used as a rich source of all milk bioactives, including 
immunoglobulins, whey proteins and peptides, lactoferrin, and probiotic lactic acid 
bacteria.  Buttermilk powder was also used a high-quality source of whey proteins and 
phospholipids, and whey protein isolate for its concentrated contribution of whey protein.  
L. acidophilus and L. reuteri were included due to their well-known exploitation as 
probiotics in dairy foods. 
As reviewed in the literature, the heat treatment used (boiling for 1 minute) does 
pose a concern in the denaturation of the immunoglobulins, however the parameters used 
are at least not as extreme as UHT treatment (138ºC for 4 sec).  Nevertheless, if this 
product were commercially processed and packaged, it would be more feasible to 
pasteurize the product at lower temperatures, such as those between batch pasteurization 
and HTST parameters (63ºC for 30 min and 72ºC for 15 sec, respectively).  This would 
minimize the immunoglobulin denaturation, and perhaps that of the other whey proteins 
as well (Li-Chan et al. 1995).  Also, the presence of the other ingredients in the 
formulation, such as sugars and milk proteins, may actually have a protective effect on 
the integrity of the immunoglobulin structure, though this was not explored in this study 
(Chen et al. 2000; Dominguez et al. 2001).  Microencapsulation is also an option for 
preserving their native structure (Chen et al. 1999). 
 Nutritional analysis by Genesis R&D software revealed a gel composition of 12% 
protein, with just 140 kilocalories per 100 gram serving.  Depending on the ultimate 
application, the formulation could be adjusted to augment the protein or kilocalorie 
composition. 
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 Sensory analysis of this gel was not performed due to time constraints and 
microbial concerns due to the method of processing, however, this would be a worthy 
addition to the future development of the product. 
5.2.1  ELISA analysis of immunoglobulins 
 Upon designing the dairy-based gel, the concentration of immunoglobulins within 
was of interest, thus an immunoassay was used to reveal this.  An enzyme-linked 
immunosorbent assay (ELISA) was chosen for this purpose due to its relative simplicity, 
precision, sensitivity, and the availability of the necessary laboratory materials.  A 
sandwich design was developed using empirically-derived concentrations of anti-bovine 
primary and secondary antibodies made in rabbit.  During the development of the assay, a 
few different blocking agents were evaluated, specifically porcine gelatin, fish skin 
gelatin, bovine serum albumin, and finally the TBS buffer with Tween-20 that was also 
used for washing.  The latter proved the simplest and most effective, and did not present 
problems with removal from the wells, thus its use was continued.  A lyophilized bovine 
immunoglobulin G (IgG) standard was employed alongside dilutions of commercial 
whole milk and colostrum, as well as the dairy-based gel formulation.  A standard 
quadratic regression curve (R2 = 0.999) was successfully constructed from the absorbance 
values produced by the bovine IgG standard, with no significant differences among trials 
(p>0.05) (Appendix F). 
The regression equation was used to estimate the IgG concentration in each of the 
dairy samples included (from the respective averages of the data), of which the milk and 
colostrum values (1.50 and 6.41 mg/ml, respectively) were found to be near those 
expected by the literature.  However, the concentration calculated for milk is a bit higher 
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than the literature value, which may be due to the wide natural variations possible in 
milk, or to imperfections in pipetting or in sample concentrations.  Since the standard 
curve was successfully constructed and used to determine this value, variation from the 
literature value did not likely stem from poor concentrations of detection antibodies, 
although that is a possibility.  At first glance, the colostrum value is within range; 
however this value is actually somewhat low compared to samples obtained soon after 
parturition.  Early colostrum can contain IgG levels anywhere from 32 - 212 mg/ml, but 
this value drops drastically (0.7 – 10 mg/ml) within a few days post-parturition (Hurley 
2003; Saito 2009).  However, due to the commercial nature of this colostrum, this value 
seems reasonable given that it is not very feasible to produce large volumes of early 
colostrum.  The IgG value estimated in the gel (11.7 mg/ml) also seems reasonable given 
that it is a more concentrated source of colostrum. 
Despite the apparent accuracy of these results, it is possible that there is a portion 
of inherent false positive data.  This would be due to the use of a secondary antibody 
developed to be sensitive to the whole molecule of IgG, which shares characteristics with 
other classes of immunoglobulins, to which it could theoretically bind.  The primary 
antibody was also developed with the whole IgG molecule, again presenting the risk of 
cross-reactions, but theoretically the vast majority of sample immunoglobulins that bound 
should have been IgG, and also supporting this is the minimal concentration of non-IgG 
antibodies in milk (0.15mg/ml IgM and IgA; 0.79 mg/ml IgG) (Hurley 2003).  If 
antibodies developed for specific fragments of IgG had been used, such as the Fc portion, 
the assay would have been more reliable to be detecting IgG, but the signal strength may 
have also been diminished (PierceBiotechnology 2007). 
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Statistical analysis of these results showed that the absorbance values for the 
bovine IgG used to construct the standard curve were not significantly different among 
trials (p>0.05) (Appendix F).  This indicates good consistency, thus a strong curve on 
which to interpolate the sample data.  However, analysis of the absorbance data for the 
milk, colostrum, and gel samples showed inconsistency among trials, specifically that 
they were all respectively statistically significantly different among trials (p<0.05).  
Tukey’s pairwise comparison tests showed that for milk, the sample values were different 
in all trials, although for the colostrum and gel the values were not different from each 
other in two of the four trials.  Although these inconsistencies exist statistically, the actual 
calculated values being found different do not generally cover a wide range.  For 
instance, the means compared for gel are 0.5, 0.6, 0.8, and 0.8 (Appendix F).  Due to the 
small sample size (n=16) and limited number of trials (n=4), these unfavorable statistical 
results would likely be improved if a larger data set were obtained (Appendix D). 
Due to the nature of the sandwich ELISA method, there are many steps at which 
inaccuracies may be introduced.  It is probable that a great deal of error was introduced 
by pipetting variances such as those induced by small air bubbles or inconsistently 
calibrated pipets.  Other modes of error may include flaws in the microplates, 
inconsistent spectrophotometer readings, imperfect plate washing, or even fluctuations in 
environmental conditions that could affect antibody binding.  Again, perhaps with a 
greater number of trial replicates, the strength of the data could be improved despite the 
inherent sources of error in this method. 
The results of the ELISA analyses illustrate the changing concentrations of 
immunoglobulins between colostrum and milk production.  These experiments also 
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reveal a mode in which these valuable bioactive molecules can be concentrated and 
delivered in a fashion that, when compared to liquid colostrum, is potentially more 
agreeable to consumers as well as more shelf-stable.  Given the promise of these results, 
more research should be done on developing a successful method to manufacture a 
colostrum-based gel on a large scale. 
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6.0  Conclusions 
Milk, colostrum, and other dairy ingredients offer valuable and unique sources of 
bioactive compounds.  These components present a rich array of potential health benefits, 
including immune system modulation, anti-hypertensive effects, antibacterial effects, 
anticancer effects, and more.  Dairy ingredients are well-studied and have immense 
potential for use in functional food applications due to their availability, functional 
attributes, and the demand for health benefits.  Large-scale manufacture is already in 
place for the major milk proteins as well as some of the minor protein and lipid 
components.  Food products developed using these remarkable ingredients could prove of 
great benefit to the immunocompromised, the elderly, and infants, as well as in athletic 
performance and prevention of disease (Korhonen 2009). 
The results of this thesis show the feasibility of creating a technique to measure 
probiotic binding with phospholipids, as well as demonstrating their selective binding 
nature.  In particular, it was shown that L. reuteri, L. casei, and L. acidophilus were all 
effective at phospholipid binding.  It seems conceivable that this method could be applied 
to studies of probiotic interactions with other dairy components, such as minor proteins.  
The elucidation of the specific interactions of probiotics with dairy product constituents 
(e.g. phospholipids) improves the understanding of their preferred environment and could 
result in the development of more efficacious ways to transport them in a viable form to 
the human body.  In addition, this research displays the effective application of dairy 
ingredients in a bioactive-rich food product.  Analysis by ELISA showed that at least one 
category of bioactives, the immunoglobulins, could be delivered by this matrix in a more 
concentrated form.  With additional analysis methods, it is reasonable to expect similar 
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effects with other classes of bioactives.  Indeed, these results, as well as the probiotic 
interactions illuminated by the experiments of this thesis, offer a modest contribution to 
the future development of innovative modes of bioactive delivery and the continued 
benefit of these amazing compounds to human health. 
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7.0  Future Research 
• Perform more extensive studies of the binding of probiotic bacteria to phospholipids 
extracted from various dairy products. 
• Explore the specific types of S-layer proteins that correlate well with bacterial 
binding to phospholipids, and produce recombinant probiotic bacteria containing 
these to optimize lipid binding in food product applications. 
• Confocal microscopy to visualize interactions between probiotic bacteria and 
phospholipids from an actual food product. 
• Study the production and cost feasibility of larger-scale manufacture of colostrum-
based foods, as well as the effects of processing parameters (e.g. heating) on the 
retention of immunoglobulin function.  Also investigate the effects of formulation, 
manufacturing, and packaging on the prevention of microbial spoilage and the 
viability of immunoglobulins and probiotics. 
• Cell culture studies to elucidate the impact of the colostrum gel on some aspects of 
immune function. 
• Explore the practicality of the application of the more minor milk bioactives in 
products for the consumer market.  Also market their extensive health potential. 
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Appendix A:  Growth study of lactic acid bacteria 
 Abs 600nm of bacteria 
Hour LC-10 NCFM SD2112 T-1 
0 0.131 0.131 0.131 0.131 
2.25 0.206 0.182 0.182 0.228 
3.25 0.231 0.186 0.207 0.278 
4.25 0.291 0.206 0.263 0.372 
5.25 0.383 0.245 0.375 0.535 
6.25 0.541 0.305 0.61 0.801 
7.25 0.841 0.455 0.985 1.167 
7.75 1.01 0.592 1.252 1.303 
8.25 1.105 0.665 1.45 1.446 
8.75 1.269 0.721 1.571 1.585 
9.25 1.348 0.86 1.64 1.675 
9.75 1.463 0.975 1.696 1.743 
10.25 1.615 1.098 1.756 1.832 
10.75 1.676 1.261 1.805 1.882 
11.25 1.79 1.397 1.851 1.935 
11.75 1.831 1.445 1.922 1.966 
12.75 1.981 1.598 1.999 2.026 
13.75 2.005 1.688 2.063 2.088 
14.75 2.088 1.759 2.123 2.129 
15.75 2.146 1.778 2.14 2.121 
16.75 2.186 1.838 2.133 2.147 




Appendix B:  Raw data for fluorescent dots 
 
 Sample coating on dots 










3879 1334 37850 22472 28082 
2680 2972 21636 12802 17699 
3349 3383 35355 26649 32176 
4629 1204 31950 11279 25779 
NCFM – L. 
acidophilus 
6807 2972 21636 12802 17699 
5309 3716 24531 14702 20221 
3324 1983 35913 17712 24789 
5623 49 17346 10565 12020 
LC10 – L. 
casei 
6807 1334 24549 18245 29513 
5055 2530 32977 20919 27660 
4411 3383 27419 21903 16290 
3433 1204 32490 23156 24357 
T-1 – L. 
reuteri 
4864 2180 24857 13945 18682 
6574 1538 22536 17426 22556 
4752 2836 24632 17529 28897 




Appendix C:  HPLC analysis of milk-derived phospholipid extract 
Data from HPLC analysis of phospholipid extract 
 
Run1 tR min tS min tE min H(V) Hnorm A(V.s.) Anorm W0.1 Asym Effic Res 
1 1.69 1.5 2.16 0.51 17.16 7.47 12.51 0.46 3.08 247 
2 7.59 7.21 8.14 0.33 11.31 8.08 13.53 0.64 1.24 2555 11.42 
3 13.19 12.82 13.89 0.65 22.12 9.14 15.31 0.47 1.18 14724 10.82 
4 14.68 14.42 14.95 0.16 5.44 1.72 2.89 0.36 1 30866 3.88 
5 15.31 15.13 15.71 0.25 8.4 4.06 6.79 0.46 2.17 20322 1.66 
6 16.41 15.98 17.05 0.53 17.84 13.38 22.4 0.71 1.43 9823 2.01 
7 18.11 17.43 19.11 0.52 17.71 15.88 26.58 0.86 0.59 8136 2.32 
Run2 tR min tS min tE min H(V) Hnorm A(V.s.) Anorm W0.1 Asym Effic Res 
1 1.72 1.52 2.54 0.52 17.82 8.5 13.99 0.5 2.58 221 
2 7.64 7.26 8.23 0.32 10.82 7.72 12.7 0.64 1.37 2622 11.18 
3 13.26 12.91 13.8 0.63 21.53 8.9 14.64 0.46 1.22 15170 10.94 
4 14.72 14.48 14.96 0.16 5.54 1.69 2.78 0.38 1.02 28324 3.76 
5 15.38 15.11 15.8 0.26 8.74 4.42 7.27 0.48 2.16 19189 1.66 
6 16.44 16.01 17.14 0.52 17.76 13.24 21.78 0.72 1.72 9729 1.91 
7 18.15 17.36 19.26 0.52 17.79 16.32 26.84 0.86 0.56 8123 2.33 
Run3 tR min tS min tE min H(V) Hnorm A(V.s.) Anorm W0.1 Asym Effic Res 
1 1.71 1.54 2.46 0.5 17.17 8.17 13.47 0.51 3.39 209 
2 7.83 7.45 8.4 0.32 10.96 7.66 12.63 0.66 1.43 2561 11.21 
3 13.34 12.98 14.09 0.62 21.39 9.41 15.53 0.49 1.19 13485 10.2 
4 14.76 14.49 15.09 0.17 5.68 1.99 3.29 0.45 1.11 19626 3.24 
5 15.4 15.16 15.78 0.27 9.29 4.19 6.92 0.43 2.01 23620 1.56 
6 16.43 16.03 17.05 0.52 17.97 13.42 22.14 0.73 1.69 9274 1.9 




Appendix D:  Raw data for ELISA analysis 
 
ELISA absorbance values (492nm) 









250 125 62.5 31.2 15.6 7.81 0 
2.780 2.647 2.197 1.525 0.867 0.488 0.059 0.849 0.469 0.816 
2.780 2.647 2.197 1.525 0.867 0.488 0.059 0.861 0.344 0.794 
3.136 2.617 1.523 0.723 0.360 0.199 0.069 0.849 0.469 0.816 
3.156 2.690 1.599 0.758 0.377 0.203 0.051 0.861 0.344 0.794 
2.787 2.403 1.366 0.620 0.365 0.183 0.043 0.843 0.321 0.610 
2.759 2.335 1.374 0.657 0.347 0.167 0.043 0.835 0.309 0.621 
3.109 2.643 1.722 0.908 0.444 0.222 0.116 0.825 0.319 0.609 
3.179 2.751 1.710 0.970 0.462 0.231 0.122 0.821 0.370 0.596 
       0.504 0.117 0.449 
       0.494 0.114 0.468 
       0.504 0.147 0.496 
       0.493 0.137 0.505 
       1.122 0.545 0.781 
       1.102 0.555 0.706 
       1.094 0.566 0.748 




Appendix E:  Statistical Analysis by Minitab 16 – Fluorescent dots 
Fluorescent dot trials for bacterial binding to phospholipids 
 
General Linear Model: Data versus Bacteria, Trial, Lipid  
Factor    Type   Levels  Values 
Bacteria  fixed       4  LC10, NCFM, SD2112, T-1 
Trial     fixed       4  1, 2, 3, 4 
Lipid     fixed       4  Oil, PC std, PL mix, SM std 
 
Analysis of Variance for Data, using Adjusted SS for Tests 
Source    DF      Seq SS      Adj SS      Adj MS       F      P 
Bacteria   3   257771884   257771884    85923961    4.99  0.004 
Trial      3   126360904   126360904    42120301    2.45  0.074 
Lipid      3  6010071558  6010071558  2003357186  116.42  0.000 
Error     54   929231201   929231201    17207985 
Total     63  7323435546 
 
S = 4148.25   R-Sq = 87.31%   R-Sq(adj) = 85.20% 
 
Unusual Observations for Data 
Obs     Data      Fit  SE Fit  Residual  St Resid 
 31  16290.4  26771.9  1639.7  -10481.5     -2.75 R 
 55  35913.0  26585.3  1639.7    9327.7      2.45 R 
R denotes an observation with a large standardized residual. 
 
Expected Mean Squares, using Adjusted SS 
            Expected Mean 
             Square for 
   Source    Each Term 
1  Bacteria  (4) + Q[1] 
2  Trial     (4) + Q[2] 
3  Lipid     (4) + Q[3] 
4  Error     (4) 
 
Error Terms for Tests, using Adjusted SS 
                                 Synthesis 
   Source    Error DF  Error MS  of Error MS 
1  Bacteria     54.00  17207985  (4) 
2  Trial        54.00  17207985  (4) 
3  Lipid        54.00  17207985  (4) 
 
Variance Components, using Adjusted SS 
        Estimated 
Source      Value 
Error    17207985 
 
Grouping Information Using Tukey Method and 95.0% Confidence 
Lipid    N     Mean  Grouping 
PL mix  16  28154.1  A 
SM std  16  24159.2    B 
PC std  16  18324.5      C 
Oil     16   2673.1        D 









Tukey 95.0% Simultaneous Confidence Intervals 
Response Variable Data 
All Pairwise Comparisons among Levels of Lipid 
Lipid = Oil  subtracted from: 
 
Lipid   Lower  Center  Upper  -------+---------+---------+--------- 
PC std  11762   15651  19540                   (--*--) 
PL mix  21592   25481  29370                           (--*--) 
SM std  17597   21486  25375                        (--*--) 
                              -------+---------+---------+--------- 
                                     0     12000     24000 
Lipid = PC std  subtracted from: 
 
Lipid   Lower  Center  Upper  -------+---------+---------+--------- 
PL mix   5941    9830  13719              (--*--) 
SM std   1946    5835   9724           (--*--) 
                              -------+---------+---------+--------- 
                                     0     12000     24000 
Lipid = PL mix  subtracted from: 
 
Lipid   Lower  Center   Upper  -------+---------+---------+--------- 
SM std  -7884   -3995  -105.9  (---*--) 
                               -------+---------+---------+--------- 
                                      0     12000     24000 
Tukey Simultaneous Tests 
Response Variable Data 
All Pairwise Comparisons among Levels of Lipid 
Lipid = Oil  subtracted from: 
 
        Difference       SE of           Adjusted 
Lipid     of Means  Difference  T-Value   P-Value 
PC std       15651        1467    10.67    0.0000 
PL mix       25481        1467    17.37    0.0000 
SM std       21486        1467    14.65    0.0000 
 
Lipid = PC std  subtracted from: 
        Difference       SE of           Adjusted 
Lipid     of Means  Difference  T-Value   P-Value 
PL mix        9830        1467    6.702    0.0000 
SM std        5835        1467    3.978    0.0012 
 
Lipid = PL mix  subtracted from: 
        Difference       SE of           Adjusted 
Lipid     of Means  Difference  T-Value   P-Value 
SM std       -3995        1467   -2.724    0.0419 
 
Grouping Information Using Tukey Method and 95.0% Confidence 
 
Bacteria   N     Mean  Grouping 
SD2112    16  20537.0  A 
LC10      16  19303.3  A 
T-1       16  18348.7  A B 
NCFM      16  15121.9    B 
 










Tukey 95.0% Simultaneous Confidence Intervals 
Response Variable Data 
All Pairwise Comparisons among Levels of Bacteria 
Bacteria = LC10  subtracted from: 
 
Bacteria  Lower  Center   Upper  ------+---------+---------+---------+ 
NCFM      -8070   -4181  -292.5  (-------*------) 
SD2112    -2655    1234  5122.7             (------*-------) 
T-1       -4844    -955  2934.4        (-------*-------) 
                                 ------+---------+---------+---------+ 
                                   -5000         0      5000     10000 
Bacteria = NCFM  subtracted from: 
 
Bacteria   Lower  Center  Upper  ------+---------+---------+---------+ 
SD2112    1526.2    5415   9304                     (-------*-------) 
T-1       -662.2    3227   7116                 (------*-------) 
                                 ------+---------+---------+---------+ 
                                   -5000         0      5000     10000 
Bacteria = SD2112  subtracted from: 
 
Bacteria  Lower  Center  Upper  ------+---------+---------+---------+ 
T-1       -6077   -2188   1701      (-------*------) 
                                ------+---------+---------+---------+ 
                                  -5000         0      5000     10000 
Tukey Simultaneous Tests 
Response Variable Data 
All Pairwise Comparisons among Levels of Bacteria 
Bacteria = LC10  subtracted from: 
          Difference       SE of           Adjusted 
Bacteria    of Means  Difference  T-Value   P-Value 
NCFM           -4181        1467   -2.851    0.0304 
SD2112          1234        1467    0.841    0.8346 
T-1             -955        1467   -0.651    0.9148 
 
Bacteria = NCFM  subtracted from: 
          Difference       SE of           Adjusted 
Bacteria    of Means  Difference  T-Value   P-Value 
SD2112          5415        1467    3.692    0.0028 
T-1             3227        1467    2.200    0.1362 
 
Bacteria = SD2112  subtracted from: 
          Difference       SE of           Adjusted 
Bacteria    of Means  Difference  T-Value   P-Value 





Appendix F:  Statistical Analysis by Minitab 16 – ELISA analysis 
 
Evaluation of bovine IgG standard curve  
 
General Linear Model: Abs BovIgG versus Trial, BovIgG conc  
 
Factor       Type   Levels  Values 
Trial        fixed       4  1, 2, 3, 4 
BovIgG conc  fixed       7  0.00, 7.80, 15.60, 31.25, 62.50, 125.00, 250.00 
 
Analysis of Variance for Abs BovIgG, using Adjusted SS for Tests 
Source       DF   Seq SS   Adj SS  Adj MS      F      P 
Trial         3   2.7954   2.7954  0.9318   1.71  0.179 
BovIgG conc   6  45.9113  45.9113  7.6519  14.00  0.000 
Error        46  25.1350  25.1350  0.5464 
Total        55  73.8417 
 
S = 0.739197   R-Sq = 65.96%   R-Sq(adj) = 59.30% 
 
Unusual Observations for Abs BovIgG 
Obs  Abs BovIgG      Fit   SE Fit  Residual  St Resid 
 51     3.80980  1.64496  0.31237   2.16484      3.23 R 
 52     3.81850  1.64496  0.31237   2.17354      3.24 R 
 
R denotes an observation with a large standardized residual. 
 
Grouping Information Using Tukey Method and 95.0% Confidence 
Trial   N  Mean  Grouping 
4      14   1.7  A 
1      14   1.5  A 
2      14   1.2  A 
3      14   1.1  A 




Evaluation of ELISA samples 
 
General Linear Model: Milk Abs, Col Abs, Gel Abs versus Trial  
Factor  Type   Levels  Values 
Trial   fixed       4  1, 2, 3, 4 
 
Analysis of Variance for Milk Abs, using Adjusted SS for Tests 
Source  DF   Seq SS   Adj SS   Adj MS        F      P 
Trial    3  0.73957  0.73957  0.24652  2870.75  0.000 
Error   12  0.00103  0.00103  0.00009 
Total   15  0.74060 
 
S = 0.00926682   R-Sq = 99.86%   R-Sq(adj) = 99.83% 
 
Unusual Observations for Milk Abs 
Obs  Milk Abs      Fit   SE Fit  Residual  St Resid 
  9   1.12200  1.10335  0.00463   0.01865      2.32 R 
R denotes an observation with a large standardized residual. 
 
Analysis of Variance for Col Abs, using Adjusted SS for Tests 
Source  DF   Seq SS   Adj SS   Adj MS      F      P 
Trial    3  0.40817  0.40817  0.13606  72.03  0.000 
Error   12  0.02267  0.02267  0.00189 
Total   15  0.43084 
S = 0.0434608   R-Sq = 94.74%   R-Sq(adj) = 93.42% 
 
Analysis of Variance for Gel Abs, using Adjusted SS for Tests 
Source  DF    Seq SS    Adj SS    Adj MS       F      P 
Trial    3  0.260902  0.260902  0.086967  151.21  0.000 
Error   12  0.006902  0.006902  0.000575 
Total   15  0.267803 
 
S = 0.0239818   R-Sq = 97.42%   R-Sq(adj) = 96.78% 
 
Unusual Observations for Gel Abs 
Obs   Gel Abs       Fit    SE Fit   Residual  St Resid 
 10  0.705500  0.754875  0.011991  -0.049375     -2.38 R 
R denotes an observation with a large standardized residual. 
 
Grouping Information Using Tukey Method and 95.0% Confidence for Milk Abs 
Trial  N  Mean  Grouping 
3      4   1.1  A 
1      4   0.9    B 
2      4   0.8      C 
4      4   0.5        D 
Means that do not share a letter are significantly different. 
 
Grouping Information Using Tukey Method and 95.0% Confidence for Col Abs 
Trial  N  Mean  Grouping 
3      4   0.6  A 
1      4   0.4    B 
2      4   0.3    B 
4      4   0.1      C 
Means that do not share a letter are significantly different. 
 
Grouping Information Using Tukey Method and 95.0% Confidence for Gel Abs 
Trial  N  Mean  Grouping 
1      4   0.8  A 
3      4   0.8  A 
2      4   0.6    B 
4      4   0.5      C 
Means that do not share a letter are significantly different.  
  98
Appendix G:  Buffer formulas 
10x PBS pH 7.2 
 0.017 M potassium phosphate monobasic (cat #P-0662, Fisher Sci.) 
 0.1 M potassium phosphate dibasic (cat #PX1570-2, EMD Chemicals) 
 1.49 M NaCl (cat #S640-3, Fisher Sci.) 
10x TBS-Tween-20 pH 8.0 
50 mM Tris HCl (cat #9310, EMD Chemicals) 
140 mM NaCl (cat #S640-3, Fisher Sci.) 
0.05% Tween-20 (cat #BP337, Fisher Sci.) 
0.05M carbonate-bicarbonate pH 9.6 
29 mM sodium carbonate (cat #BP357-1, Fisher Sci) 
71 mM sodium bicarbonate (cat #S-8875, Sigma Aldrich) 
0.05M citrate-phosphate pH 5.0 
 24 mM citrate, anhydrous (cat #BP339, Fisher Sci.) 
 51 mM potassium phosphate dibasic (cat #PX1570-2, EMD Chemicals) 
